Generate Chart For
(Chart displayed below)
Rat Strains
{{sample.term}}
Measurement Methods
{{method.term}}
1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. spleen mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000171 spleen wet weight 0.708 g 0.0326 0.073 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76115 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood total protein amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000661 serum total protein level 9.38 g/dl 0.6695 1.497 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76125 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood cholesterol amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000363 serum total cholesterol level 68.12 mg/dl 6.422 14.36 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76130 vehicle control condition (for 91 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney superoxide dismutase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002229 kidney superoxide dismutase activity to total protein level ratio 13.53 U/mg 0.8042 1.97 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 76187 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney superoxide dismutase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002229 kidney superoxide dismutase activity to total protein level ratio 8.13 U/mg 0.792 1.94 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76188 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 70 days 8 CMO:0000012 body weight 353.1 g 10.8 30.547 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 75955 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002178 total food calorie intake rate 2995.2 kcal/d 187.0 528.9159 MMO:0000160 unspecified method 0.0 controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76182 controlled in utero environment (for 9 days) vehicle control condition (for 30 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002209 food calorie intake level to change in body weight ratio 10.1 kcal/g 0.3 0.8485 MMO:0000160 unspecified method 0.0 controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) 76204 controlled in utero environment (for 9 days) vehicle control condition (for 30 days) maternal milk (for 21 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. catalase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002224 kidney catalase activity to total protein level ratio 35.98 nmol/mg 0.8083 1.98 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 76234 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. catalase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002224 kidney catalase activity to total protein level ratio 21.73 nmol/mg 0.6165 1.51 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76235 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002212 food intake weight to change in body weight ratio 6.7 g/g 0.3 0.8485 MMO:0000160 unspecified method 0.0 controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) 76203 controlled in utero environment (for 9 days) vehicle control condition (for 30 days) maternal milk (for 21 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. body mass RS:0001014 Hsd:WI male 0 days 6 CMO:0000012 body weight 140.6 g 0.5307 1.3 MMO:0000016 body weighing method 0.0 vehicle control condition (for 10 days) 75951 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. body mass RS:0001014 Hsd:WI male 0 days 6 CMO:0000012 body weight 137.6 g 0.4491 1.1 MMO:0000016 body weighing method 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75952 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 98 days 8 CMO:0000012 body weight 457.7 g 15.9 44.972 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 75962 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. urine output RS:0001014 Hsd:WI male 0 days 6 CMO:0000260 timed urine volume 6.8 ml/d 0.6124 1.5 MMO:0000357 urine volume measurement method 0.0 vehicle control condition (for 10 days) 75965 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. urine output RS:0001014 Hsd:WI male 0 days 6 CMO:0000260 timed urine volume 21.8 ml/d 1.3064 3.2 MMO:0000357 urine volume measurement method 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75966 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0000420 body weight gain 104.6 g 5.9 16.6877 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 75969 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. blood creatinine amount RS:0001014 Hsd:WI male 0 days 6 CMO:0000057 serum creatinine level 0.54 mg/dl 0.0122 0.03 MMO:0000271 serum creatinine analysis 0.0 vehicle control condition (for 10 days) 75972 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. blood creatinine amount RS:0001014 Hsd:WI male 0 days 6 CMO:0000057 serum creatinine level 1.69 mg/dl 0.0572 0.14 MMO:0000271 serum creatinine analysis 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75973 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. blood urea nitrogen amount RS:0001014 Hsd:WI male 0 days 6 CMO:0000587 serum urea nitrogen level 69.64 mg/dl 2.4985 6.12 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 75976 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. blood urea nitrogen amount RS:0001014 Hsd:WI male 0 days 6 CMO:0000587 serum urea nitrogen level 96.11 mg/dl 1.9147 4.69 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75977 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. body mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000012 body weight 388 g 16.8152 37.6 MMO:0000016 body weighing method 0.0 vehicle control condition (for 91 days) 76041 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. body mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0002216 change in body weight to body weight ratio 255 % 13.4164 30.0 MMO:0000016 body weighing method 0.0 vehicle control condition (for 91 days) 76065 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. kidney mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000082 right kidney wet weight 1.214 g 0.0371 0.083 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76070 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. kidney mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000083 left kidney wet weight 1.192 g 0.0563 0.126 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76075 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. kidney mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0001953 right kidney wet weight to body weight ratio 3.138 mg/g 0.059 0.132 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76080 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. kidney mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0001954 left kidney wet weight to body weight ratio 3.072 mg/g 0.0711 0.159 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76085 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. liver mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000158 liver wet weight 13.6 g 1.0465 2.34 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76090 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. liver mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000633 liver weight to body weight ratio 34.846 g/kg 1.2093 2.704 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76095 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. spleen mass RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000149 spleen weight to body weight ratio 0.1832 % 0.0084 0.0188 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 91 days) 76120 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood triglyceride amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000360 serum triglyceride level 156.94 mg/dl 14.9307 33.386 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76135 vehicle control condition (for 91 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 70 days 8 CMO:0000012 body weight 345.8 g 13.1 37.0524 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 76140 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood calcium amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000503 serum calcium level 12.82 mg/dl 0.2375 0.531 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76141 vehicle control condition (for 91 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 98 days 8 CMO:0000012 body weight 491.1 g 20.4 57.6999 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76148 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood albumin amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000550 serum albumin level 0.04486 g/dl 0.0016 0.0036 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76149 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood bilirubin amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000376 serum total bilirubin level 0.96 mg/dl 0.0747 0.167 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76156 vehicle control condition (for 91 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. body mass RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0000420 body weight gain 145.3 g 9.3 26.3044 MMO:0000016 body weighing method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76161 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood urea nitrogen amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000587 serum urea nitrogen level 77.76 mg/dl 3.1797 7.11 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76164 vehicle control condition (for 91 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002178 total food calorie intake rate 2103.7 kcal/d 62.9 177.9081 MMO:0000160 unspecified method 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 76169 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood creatinine amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000057 serum creatinine level 0.68 mg/dl 0.0492 0.11 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76170 vehicle control condition (for 91 days) 1545 Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. blood lactate dehydrogenase amount RS:0001014 Hsd:WI male 126 days to 119 days 5 CMO:0000668 serum lactate dehydrogenase activity level 1068 U/l 313.2284 700.4 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 91 days) 76177 vehicle control condition (for 91 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney glutathione peroxidase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002227 kidney glutathione peroxidase activity to total protein level ratio 22.63 U/mg 1.3472 3.3 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 76191 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney glutathione peroxidase activity RS:0001014 Hsd:WI male 0 days 6 CMO:0002227 kidney glutathione peroxidase activity to total protein level ratio 7.54 U/mg 0.5062 1.24 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76192 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002212 food intake weight to change in body weight ratio 4.7 g/g 0.2 0.5657 MMO:0000160 unspecified method 0.0 controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76197 controlled in utero environment (for 9 days) vehicle control condition (for 30 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. eating behavior trait RS:0002943 BluHsd:LE male 98 days to 71 days 8 CMO:0002209 food calorie intake level to change in body weight ratio 10.4 kcal/g 0.3 0.8485 MMO:0000160 unspecified method 0.0 controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76198 controlled in utero environment (for 9 days) vehicle control condition (for 30 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. testis mass RS:0002943 BluHsd:LE male 98 days 8 CMO:0000175 both testes wet weight 3.4 g 0.3 0.8485 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 76233 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney glutathione amount RS:0001014 Hsd:WI male 0 days 6 CMO:0002235 kidney glutathione level 12384.996 ug/g 257.1989 630.006 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 76238 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney glutathione amount RS:0001014 Hsd:WI male 0 days 6 CMO:0002235 kidney glutathione level 7882.758 ug/g 178.1573 436.3944 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76239 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. testis mass RS:0002943 BluHsd:LE male 98 days 8 CMO:0000175 both testes wet weight 3.4 g 0.2 0.5657 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76249 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. blood testosterone amount RS:0002943 BluHsd:LE male 98 days 8 CMO:0000568 serum testosterone level 7.3 ng/ml 1.5 4.2426 MMO:0000073 radioimmunoassay 0.0 tritium-based vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 76252 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. blood testosterone amount RS:0002943 BluHsd:LE male 98 days 8 CMO:0000568 serum testosterone level 10 ng/ml 1.2 3.3941 MMO:0000073 radioimmunoassay 0.0 tritium-based vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76253 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. blood estradiol amount RS:0002943 BluHsd:LE male 98 days 8 CMO:0000564 serum estradiol level 370 pg/ml 120.0 339.4113 MMO:0000073 radioimmunoassay 0.0 tritium-based vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) 76254 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) 1543 Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. blood estradiol amount RS:0002943 BluHsd:LE male 98 days 8 CMO:0000564 serum estradiol level 290 pg/ml 10.0 28.2843 MMO:0000073 radioimmunoassay 0.0 tritium-based vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) 76255 vehicle control condition (for 30 days) controlled in utero environment (for 9 days) maternal milk (for 21 days) controlled fat content diet (21.2 %) (for 28 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney lipid peroxide amount RS:0001014 Hsd:WI male 0 days 6 CMO:0002246 kidney lipid peroxide level 0.75 nmol/mg 0.0163 0.04 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) 76256 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney lipid peroxide amount RS:0001014 Hsd:WI male 0 days 6 CMO:0002246 kidney lipid peroxide level 1.51 nmol/mg 0.0327 0.08 MMO:0000329 liquid phase colorimetry 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76257 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1558 Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. blood estradiol amount RS:0000064 Crl:CD(SD) female 50 days 32 CMO:0000564 serum estradiol level 34.4 pg/ml 2.7 15.2735 MMO:0000073 radioimmunoassay 0.0 maternal milk (for 20 days) and vehicle control condition (for 15 days) 76260 maternal milk (for 20 days) vehicle control condition (for 15 days) 1558 Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. blood progesterone amount RS:0000064 Crl:CD(SD) female 50 days 32 CMO:0000566 serum progesterone level 12.5 ng/ml 2.8 15.8392 MMO:0000073 radioimmunoassay 0.0 maternal milk (for 20 days) and vehicle control condition (for 15 days) 76262 maternal milk (for 20 days) vehicle control condition (for 15 days) 1558 Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. mammary gland integrity trait RS:0000064 Crl:CD(SD) female 365 days to 0 days 32 CMO:0000343 mammary tumor number 2.84 0.31 1.7536 MMO:0000158 manual palpation method 0.0 maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) 76264 maternal milk (for 20 days) vehicle control condition (for 15 days) 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) 1558 Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. mammary gland integrity trait RS:0000064 Crl:CD(SD) female 365 days to 0 days 32 CMO:0000345 post-insult time to mammary tumor formation median 65 d MMO:0000158 manual palpation method 0.0 maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) 76267 maternal milk (for 20 days) vehicle control condition (for 15 days) 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. body mass RS:0001592 HanTac:WH female 0 days 18 CMO:0000420 body weight gain G7-G21 82.4 g 6.2225 26.4 MMO:0000016 body weighing method 0.0 vehicle control condition (for 14 days) 76270 vehicle control condition (for 14 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney mass RS:0001014 Hsd:WI male 0 days 6 CMO:0000085 both kidneys wet weight 0.82 g 0.0245 0.06 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 10 days) 75956 vehicle control condition (for 10 days) 1544 Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. kidney mass RS:0001014 Hsd:WI male 0 days 6 CMO:0000085 both kidneys wet weight 1.2 g 0.0531 0.13 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75957 vehicle control condition (for 10 days) cisplatin (7.5 mg/kg) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. body mass RS:0001592 HanTac:WH male 1 days 17 CMO:0000012 body weight 6.2 g 0.1213 0.5 MMO:0000016 body weighing method 0.0 vehicle control condition (for 1 days) 96612 vehicle control condition (for 1 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. body mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0000012 body weight 29.1 g 0.6713 2.6 MMO:0000016 body weighing method 0.0 vehicle control condition (between 16 and 17 days) 96687 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity RS:0001592 HanTac:WH female 0 days 18 CMO:0002383 number of fetuses lost perinatally to litter size ratio 8.5 % 1.8856 8.0 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96592 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span RS:0001592 HanTac:WH female 0 days 18 CMO:0002384 number of perinatal live-born offspring deaths to litter size ratio 3.2 % 1.2728 5.4 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96602 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. perineum length RS:0001592 HanTac:WH male 1 days 17 CMO:0002385 anogenital distance 4.1 mm 0.017 0.07 MMO:0000417 in vivo stereo light microscopy 0.0 vehicle control condition (for 1 days) 96617 vehicle control condition (for 1 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. testis mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000177 right testis wet weight 51.3 mg 1.7913 7.6 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96637 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. epididymis mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0001606 both epididymides wet weight 0.0228 g 9.0E-4 0.0038 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96652 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. seminal gland mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0001605 both seminal vesicles wet weight 7.1 mg 0.4714 2.0 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96657 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. skeletal muscle mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0002387 combined levator ani and bulbocavernosus muscle weight 26 mg 1.0371 4.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96662 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. liver mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000158 liver wet weight 0.7537 g 0.027 0.1147 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96672 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. adrenal gland mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000164 both adrenal glands wet weight 7.5 mg 0.495 2.1 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96677 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. ovary mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0002491 left ovary wet weight left ovary 3.2 mg 0.2685 1.04 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96697 vehicle control condition (between 16 and 17 days) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0000771 WKY/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure 27 mmHg 3.0 7.3485 MMO:0000011 vascular indwelling catheter method 0.0 vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) 84566 vehicle control condition (2 ul) (for 0 hours) air-jet exposure (for 0 hours) angiotensin II (20 ng) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0001054 WKY.SHRSP-(D1Wox29-D1Arb21)/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure 32 mmHg 2.0 4.899 MMO:0000011 vascular indwelling catheter method 0.0 vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) 84568 vehicle control condition (2 ul) (for 0 hours) air-jet exposure (for 0 hours) angiotensin II (20 ng) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0000771 WKY/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure 50 mmHg 2.0 4.899 MMO:0000011 vascular indwelling catheter method 0.0 vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) 84570 vehicle control condition (2 ul) (for 0 hours) air-jet exposure (for 0 hours) angiotensin II (20 ng) phenylephrine (3 ug) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0001054 WKY.SHRSP-(D1Wox29-D1Arb21)/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure 50 mmHg 3.0 7.3485 MMO:0000011 vascular indwelling catheter method 0.0 vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) 84572 vehicle control condition (2 ul) (for 0 hours) air-jet exposure (for 0 hours) angiotensin II (20 ng) phenylephrine (3 ug) 1601 McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23. blood alanine transaminase amount RS:0000363 F344/NHsd not specified 84 days to 56 days 4 CMO:0000575 serum alanine aminotransferase activity level 35 U/l 11.0 22.0 MMO:0000173 spectrophotometry 0.0 fasting (between 12 and 15 hours) then vehicle control condition (for 1 days) 84754 fasting (between 12 and 15 hours) vehicle control condition (for 1 days) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0000771 WKY/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure -3 mmHg 2.0 4.899 MMO:0000011 vascular indwelling catheter method 0.0 air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) 84553 air-jet exposure (for 0 hours) vehicle control condition (2 ul) (for 0 hours) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. arterial blood pressure trait RS:0001054 WKY.SHRSP-(D1Wox29-D1Arb21)/Izm male 98 days 6 CMO:0000533 absolute change in mean arterial blood pressure -1 mmHg 2.0 4.899 MMO:0000011 vascular indwelling catheter method 0.0 air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) 84555 air-jet exposure (for 0 hours) vehicle control condition (2 ul) (for 0 hours) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. heart pumping trait RS:0000771 WKY/Izm male 98 days 6 CMO:0000534 absolute change in heart rate 0 beats/min 6.0 14.6969 MMO:0000011 vascular indwelling catheter method 0.0 air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) 84562 air-jet exposure (for 0 hours) vehicle control condition (2 ul) (for 0 hours) 1120 Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20. heart pumping trait RS:0001054 WKY.SHRSP-(D1Wox29-D1Arb21)/Izm male 98 days 6 CMO:0000534 absolute change in heart rate -5 beats/min 7.0 17.1464 MMO:0000011 vascular indwelling catheter method 0.0 air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) 84564 air-jet exposure (for 0 hours) vehicle control condition (2 ul) (for 0 hours) 1601 McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23. blood alanine transaminase amount RS:0000698 Hsd:SD not specified 84 days to 56 days 4 CMO:0000575 serum alanine aminotransferase activity level 30 U/l 1.0 2.0 MMO:0000173 spectrophotometry 0.0 fasting (between 12 and 15 hours) then vehicle control condition (for 1 days) 84757 fasting (between 12 and 15 hours) vehicle control condition (for 1 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration RS:0001592 HanTac:WH female 0 days 18 CMO:0000467 gestation period length 23 d 0.1414 0.6 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96583 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity RS:0001592 HanTac:WH female 0 days 18 CMO:0000642 litter size 11.8 0.7778 3.3 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96597 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity RS:0001592 HanTac:WH female 0 days 18 CMO:0002494 number of male offspring to litter size ratio (number of males to litter size) ratio) 50.5 % 4.3605 18.5 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96607 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. perineum length RS:0001592 HanTac:WH female 1 days 17 CMO:0002385 anogenital distance 2.2 mm 0.0243 0.1 MMO:0000417 in vivo stereo light microscopy 0.0 vehicle control condition (for 1 days) 96622 vehicle control condition (for 1 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity RS:0001592 HanTac:WH male 14 days 17 CMO:0002386 areola mammae/nipple number 0.1 0.0485 0.2 MMO:0000163 in vivo visual assessment 0.0 vehicle control condition (for 14 days) 96627 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. body mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000012 body weight 28.6 g 1.0842 4.6 MMO:0000016 body weighing method 0.0 vehicle control condition (between 16 and 17 days) 96632 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. testis mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000178 left testis wet weight 50.9 mg 1.7442 7.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96642 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. ventral prostate mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000850 ventral prostate gland wet weight 0.0117 g 8.0E-4 0.0036 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96647 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. ovary mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0002490 right ovary wet weight right ovary 2.9 mg 0.1988 0.77 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96692 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. thyroid gland mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0002392 thyroid gland wet weight left ovary 4.7 mg 0.2324 0.9 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96707 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. retroperitoneal fat pad mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0000356 retroperitoneal fat pad weight 0.0295 g 0.0032 0.0123 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96712 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. embryonic growth trait RS:0001592 HanTac:WH female 0 days 18 CMO:0002382 number of blastocysts/embryos lost postimplantation to litter size ratio 7.9 % 2.7106 11.5 MMO:0000160 unspecified method 0.0 vehicle control condition (for 14 days) 96588 vehicle control condition (for 14 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. bulbourethral gland mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0002395 bulbourethral gland wet weight 1.7 mg 0.0943 0.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96667 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. retroperitoneal fat pad mass RS:0001592 HanTac:WH male 17 days to 16 days 18 CMO:0000356 retroperitoneal fat pad weight 0.038 g 0.0026 0.0112 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96682 vehicle control condition (between 16 and 17 days) 1559 Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. liver mass RS:0001592 HanTac:WH female 17 days to 16 days 15 CMO:0000158 liver wet weight 0.7988 g 0.0172 0.0667 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (between 16 and 17 days) 96702 vehicle control condition (between 16 and 17 days) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000606 left ventricular end-diastolic blood pressure 13 mmHg 2.0 4.899 MMO:0000014 vascular transducer tipped catheter 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98826 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000606 left ventricular end-diastolic blood pressure 3 mmHg 1.0 2.4495 MMO:0000014 vascular transducer tipped catheter 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98827 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000605 left ventricular end-systolic blood pressure 56 mmHg 3.0 7.3485 MMO:0000014 vascular transducer tipped catheter 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98838 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000605 left ventricular end-systolic blood pressure 64 mmHg 3.0 7.3485 MMO:0000014 vascular transducer tipped catheter 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98839 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle mass RS:0000681 SD male 0 days 6 CMO:0000530 heart left ventricle weight to body weight ratio g/g*103 2.6 mg/g 0.1 0.2449 MMO:0000005 post excision weight measurement 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) 98874 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle mass RS:0000681 SD male 0 days 6 CMO:0000530 heart left ventricle weight to body weight ratio g/g*103 2.3 mg/g 0.1 0.2449 MMO:0000005 post excision weight measurement 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) 98875 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. glomerular filtration trait RS:0000916 WKY/NHsd male 0 days 7 CMO:0000765 creatinine clearance 3.1 ml/min 0.5 1.3229 MMO:0000275 urine creatinine analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99179 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. glomerular filtration trait RS:0000916 WKY/NHsd male 0 days 7 CMO:0000765 creatinine clearance 3.5 ml/min 0.3 0.7937 MMO:0000275 urine creatinine analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99181 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0001745 maximum rate of positive change in left ventricular blood pressure 8259 mmHg/s 325.0 796.0842 MMO:0000014 vascular transducer tipped catheter 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98886 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0001745 maximum rate of positive change in left ventricular blood pressure 8231 mmHg/s 423.0 1036.1342 MMO:0000014 vascular transducer tipped catheter 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98887 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0001746 maximum rate of negative change in left ventricular blood pressure -6032 mmHg/s 387.0 947.9525 MMO:0000014 vascular transducer tipped catheter 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98890 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricular blood pressure trait RS:0000681 SD male 0 days 6 CMO:0001746 maximum rate of negative change in left ventricular blood pressure -7197 mmHg/s 303.0 742.1954 MMO:0000014 vascular transducer tipped catheter 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98891 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait RS:0000681 SD male 0 days 6 CMO:0000002 heart rate 420 beats/min 14.0 34.2929 MMO:0000107 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98801 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait RS:0000681 SD male 0 days 6 CMO:0000002 heart rate 380 beats/min 10.0 24.4949 MMO:0000107 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98802 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. arterial blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000009 mean arterial blood pressure 72 mmHg 2.0 4.899 MMO:0000014 vascular transducer tipped catheter 1.0 ACF 2 days artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) 98814 artificial aortocaval fistula (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) (for 0 hours) 2160 Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. arterial blood pressure trait RS:0000681 SD male 0 days 6 CMO:0000009 mean arterial blood pressure 86 mmHg 4.0 9.798 MMO:0000014 vascular transducer tipped catheter 1.0 sham ACF 2 days sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98815 sham surgical control condition (for 2 days) vehicle control condition (for 2 days) ketamine (80 mg/kg) (for 0 hours) xylazine (10 mg/kg) 2219 Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount RS:0000742 WKY male 156 days 10 CMO:0000046 blood glucose level 160.56 mg/dl 8.64 27.3221 MMO:0000073 radioimmunoassay 0.0 days vehicle control condition (1 null) 99101 vehicle control condition (1 null) 2219 Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass RS:0000742 WKY male 156 days 10 CMO:0000012 body weight 450.39 g 9.36 29.5989 MMO:0000016 body weighing method 0.0 days vehicle control condition (1 null) 99107 vehicle control condition (1 null) 2219 Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass RS:0000742 WKY male 156 days 10 CMO:0000622 single kidney wet weight to body weight ratio 3.41 g/kg 0.34 1.0752 MMO:0000005 post excision weight measurement 0.0 days vehicle control condition (1 null) 99113 vehicle control condition (1 null) 2219 Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output RS:0000742 WKY male 156 days 10 CMO:0000260 timed urine volume 17.1 ml/d 1.57 4.9648 MMO:0000357 urine volume measurement method 0.0 days vehicle control condition (1 null) 99119 vehicle control condition (1 null) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount RS:0000742 WKY male 0 days 11 CMO:0000046 blood glucose level 76 mg/dl 1.0 3.3166 MMO:0000190 machine read blood glucose test strip 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99970 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount RS:0000742 WKY male 0 days 17 CMO:0000046 blood glucose level 324 mg/dl 13.0 53.6004 MMO:0000190 machine read blood glucose test strip 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99971 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity RS:0000742 WKY male 0 days 11 CMO:0000037 hematocrit 45.2 % 1.4 4.6433 MMO:0000214 hematocrit analysis 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99975 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity RS:0000742 WKY male 0 days 17 CMO:0000037 hematocrit 44.8 % 0.6 2.4739 MMO:0000214 hematocrit analysis 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99976 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 11 CMO:0002783 glomerular filtration rate to body weight ratio 0.517 ml/min/100g 0.011 0.0365 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99980 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 17 CMO:0002783 glomerular filtration rate to body weight ratio 0.496 ml/min/100g 0.029 0.1196 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99981 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 11 CMO:0002943 renal filtration fraction 0.23 0.01 0.0332 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99985 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 17 CMO:0002943 renal filtration fraction 0.293 0.011 0.0454 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99986 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait RS:0000742 WKY male 0 days 11 CMO:0002782 renal plasma flow to body weight ratio 2.28 ml/min/100g 0.07 0.2322 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99990 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait RS:0000742 WKY male 0 days 17 CMO:0002782 renal plasma flow to body weight ratio 1.72 ml/min/100g 0.11 0.4535 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99991 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait RS:0000742 WKY male 0 days 11 CMO:0001898 renal vascular resistance 6.3 mmHg/ml/min 0.4 1.3266 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 99995 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait RS:0000742 WKY male 0 days 17 CMO:0001898 renal vascular resistance 16.7 mmHg/ml/min 1.4 5.7723 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99996 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output RS:0000742 WKY male 0 days 11 CMO:0000260 timed urine volume 11.664 ml/d 1.008 3.3432 MMO:0000511 metabolic cage urine volume measurement method 0.0 unx 168 days unilateral nephrectomy (for 28 days) then vehicle control condition 100000 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output RS:0000742 WKY male 0 days 17 CMO:0000260 timed urine volume 39.456 ml/d 4.608 18.9993 MMO:0000511 metabolic cage urine volume measurement method 0.0 unx 168 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 100001 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000982 heart left ventricle end-diastolic diameter 7.52 mm 0.32 0.8466 MMO:0000337 echocardiography 0.0 vehicle control condition 99768 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000982 heart left ventricle end-diastolic diameter 8.68 mm 0.33 0.8731 MMO:0000337 echocardiography 0.0 vehicle control condition 99770 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000982 heart left ventricle end-diastolic diameter 7.99 mm 0.62 1.6404 MMO:0000337 echocardiography 0.0 vehicle control condition 99772 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0002597 heart left ventricle end-diastolic posterior wall thickness 2.03 mm 0.06 0.1587 MMO:0000337 echocardiography 0.0 vehicle control condition 99774 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0001840 heart left ventricle end-systolic posterior wall thickness 3.29 mm 0.19 0.5027 MMO:0000337 echocardiography 0.0 vehicle control condition 99792 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000985 heart left ventricle fractional shortening 47.3 % 4.1 10.8476 MMO:0000337 echocardiography 0.0 vehicle control condition 99804 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000005 diastolic blood pressure serial mean 128 mmHg 22.0 58.2065 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99822 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000005 diastolic blood pressure serial mean 142 mmHg 28.0 74.081 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99824 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000005 diastolic blood pressure serial mean 145 mmHg 31.0 82.0183 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99826 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000004 systolic blood pressure serial mean 172 mmHg 13.0 34.3948 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99828 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000004 systolic blood pressure serial mean 195 mmHg 30.0 79.3725 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99830 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000004 systolic blood pressure serial mean 197 mmHg 26.0 68.7895 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99832 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000009 mean arterial blood pressure serial mean 142 mmHg 12.0 31.749 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99834 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000009 mean arterial blood pressure serial mean 158 mmHg 27.0 71.4353 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99836 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. arterial blood pressure trait RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000009 mean arterial blood pressure serial mean 162 mmHg 29.0 76.7268 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 99838 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. urine output RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000260 timed urine volume 14.7 ml/d 2.6 6.879 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 99840 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. urine output RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000260 timed urine volume 21.1 ml/d 7.6 20.1077 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 99842 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. urine output RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000260 timed urine volume 19.5 ml/d 4.6 12.1705 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 99844 vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass RS:0000742 WKY male 0 days 7 CMO:0000012 body weight 268 g 13.0 34.3948 MMO:0000016 body weighing method 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99935 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass RS:0000742 WKY male 0 days 8 CMO:0000012 body weight 215 g 10.0 28.2843 MMO:0000016 body weighing method 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99936 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount RS:0000742 WKY male 0 days 7 CMO:0000046 blood glucose level 74 mg/dl 2.0 5.2915 MMO:0000190 machine read blood glucose test strip 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99940 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount RS:0000742 WKY male 0 days 8 CMO:0000046 blood glucose level 350 mg/dl 18.0 50.9117 MMO:0000190 machine read blood glucose test strip 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99941 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 7 CMO:0002783 glomerular filtration rate to body weight ratio 0.494 ml/min/100g 0.03 0.0794 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99945 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 8 CMO:0002783 glomerular filtration rate to body weight ratio 0.792 ml/min/100g 0.03 0.0849 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99946 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait RS:0000742 WKY male 0 days 7 CMO:0002782 renal plasma flow to body weight ratio 2.16 ml/min/100g 0.18 0.4762 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99950 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait RS:0000742 WKY male 0 days 8 CMO:0002782 renal plasma flow to body weight ratio 3.09 ml/min/100g 0.18 0.5091 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99951 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 7 CMO:0002943 renal filtration fraction 0.233 0.013 0.0344 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99955 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait RS:0000742 WKY male 0 days 8 CMO:0002943 renal filtration fraction 0.26 0.013 0.0368 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99956 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait RS:0000742 WKY male 0 days 7 CMO:0001898 renal vascular resistance 10 mmHg/ml/min 0.6 1.5875 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99960 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait RS:0000742 WKY male 0 days 8 CMO:0001898 renal vascular resistance 9 mmHg/ml/min 0.4 1.1314 MMO:0000636 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99961 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output RS:0000742 WKY male 0 days 7 CMO:0000260 timed urine volume 12.384 ml/d 2.016 5.3338 MMO:0000511 metabolic cage urine volume measurement method 0.0 unx 28 days unilateral nephrectomy (for 28 days) then vehicle control condition 99965 unilateral nephrectomy (for 28 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output RS:0000742 WKY male 0 days 8 CMO:0000260 timed urine volume 23.472 ml/d 1.728 4.8875 MMO:0000511 metabolic cage urine volume measurement method 0.0 unx 28 days unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition 99966 unilateral nephrectomy (for 28 days) streptozotocin (35 mg/kg) vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0001840 heart left ventricle end-systolic posterior wall thickness 3.17 mm 0.17 0.4498 MMO:0000337 echocardiography 0.0 vehicle control condition 99794 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0001840 heart left ventricle end-systolic posterior wall thickness 3.41 mm 0.5 1.3229 MMO:0000337 echocardiography 0.0 vehicle control condition 99796 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. cardiac output trait RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000180 ejection fraction 83.3 % 4.3 11.3767 MMO:0000337 echocardiography 0.0 vehicle control condition 99798 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. cardiac output trait RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000180 ejection fraction 80.2 % 3.4 8.9956 MMO:0000337 echocardiography 0.0 vehicle control condition 99800 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. cardiac output trait RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000180 ejection fraction 77.4 % 6.0 15.8745 MMO:0000337 echocardiography 0.0 vehicle control condition 99802 vehicle control condition 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002770 skin chloride level to skin dry weight ratio skin cl mmol/g 0.051 mmol/g 0.003 0.0079 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99135 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002770 skin chloride level to skin dry weight ratio skin cl mmol/g 0.068 mmol/g 0.006 0.0159 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99137 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin water amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002771 skin water level to skin dry weight ratio skin h2o ml/g 1.432 ml/g 0.032 0.0847 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99141 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin mineral amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002772 skin potassium level plus skin sodium level to skin water level ratio skin na+k/h2o 0.17 0.001 0.0026 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99143 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin mineral amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002772 skin potassium level plus skin sodium level to skin water level ratio skin na+k/h2o 0.176 0.008 0.0212 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99145 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002775 skin chloride level to skin water level ratio skin na/h2o 90 mmol/l 0.8 2.1166 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99147 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002775 skin chloride level to skin water level ratio skin na/h2o 101 mmol/l 3.9 10.3184 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99149 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002775 skin chloride level to skin water level ratio skin cl/h2o 42 mmol/l 2.4 6.3498 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99151 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002775 skin chloride level to skin water level ratio skin cl/h2o 48 mmol/l 4.8 12.6996 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99153 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin potassium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002773 skin potassium level to skin water level ratio skin k/h2o 80 mmol/l 1.1 2.9103 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99155 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin potassium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002773 skin potassium level to skin water level ratio skin k/h2o 71 mmol/l 3.0 7.9373 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99157 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000060 plasma sodium level 143.7 mmol/l 4.4 11.6413 MMO:0000037 automated blood electrolyte analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99159 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000060 plasma sodium level 141.4 mmol/l 2.1 5.5561 MMO:0000037 automated blood electrolyte analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99161 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood potassium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000061 plasma potassium level 3.9 mmol/l 0.2 0.5292 MMO:0000037 automated blood electrolyte analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99163 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood potassium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000061 plasma potassium level 4.2 mmol/l 0.3 0.7937 MMO:0000037 automated blood electrolyte analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99165 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000059 plasma chloride level 98.2 mmol/l 1.1 2.9103 MMO:0000037 automated blood electrolyte analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99167 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood creatinine amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000537 plasma creatinine level 0.30882306 mg/dl 0.0102 0.0269 MMO:0000306 plasma creatinine analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99171 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood creatinine amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000537 plasma creatinine level 0.30090452 mg/dl 0.0079 0.021 MMO:0000306 plasma creatinine analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99173 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood cystatin C amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002778 plasma cystatin C level 4 mg/l 0.6 1.5875 MMO:0000352 automated plasma protein analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99175 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood cystatin C amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002778 plasma cystatin C level 3.5 mg/l 0.2 0.5292 MMO:0000352 automated plasma protein analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99177 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000985 heart left ventricle fractional shortening 44.3 % 2.8 7.4081 MMO:0000337 echocardiography 0.0 vehicle control condition 99806 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-diastolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000985 heart left ventricle fractional shortening 41.6 % 5.6 14.8162 MMO:0000337 echocardiography 0.0 vehicle control condition 99808 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle mass RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000776 heart left ventricle weight 1.53 g 0.08 0.2117 MMO:0000337 echocardiography 0.0 vehicle control condition 99810 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle mass RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000776 heart left ventricle weight 1.67 g 0.06 0.1587 MMO:0000337 echocardiography 0.0 vehicle control condition 99812 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle mass RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000776 heart left ventricle weight 1.78 g 0.04 0.1058 MMO:0000337 echocardiography 0.0 vehicle control condition 99814 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart pumping trait RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000002 heart rate 382 beats/min 45.0 119.0588 MMO:0000337 echocardiography 0.0 vehicle control condition 99816 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart pumping trait RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000002 heart rate 349 beats/min 20.0 52.915 MMO:0000337 echocardiography 0.0 vehicle control condition 99818 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart pumping trait RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000002 heart rate 327 beats/min 19.0 50.2693 MMO:0000337 echocardiography 0.0 vehicle control condition 99820 vehicle control condition 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002769 skin sodium level to skin dry weight ratio mmol/g 0.11 REQUEST NEW VALUE 0.003 0.0079 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99131 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. skin sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0002769 skin sodium level to skin dry weight ratio mmol/g 0.144 REQUEST NEW VALUE 0.005 0.0132 MMO:0000584 ex vivo analysis of atomic composition following dry ashing 0.0 ashed skin controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99133 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. blood chloride amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000059 plasma chloride level 104.8 mmol/l 1.8 4.7624 MMO:0000037 automated blood electrolyte analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99169 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. urine sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000760 urine sodium excretion rate mmol/d 1 mEq/d 0.2 0.5292 MMO:0000434 urine sodium analysis 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99183 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. urine sodium amount RS:0000916 WKY/NHsd male 0 days 7 CMO:0000760 urine sodium excretion rate 41.9 mEq/d 5.2 13.7579 MMO:0000434 urine sodium analysis 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99185 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. arterial blood pressure trait RS:0000916 WKY/NHsd male 0 days 7 CMO:0000009 mean arterial blood pressure 101 mmHg 0.9 2.3812 MMO:0000577 intra-aortic radiotelemetry 0.0 standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99187 standard rat chow (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 2238 Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20. arterial blood pressure trait RS:0000916 WKY/NHsd male 0 days 7 CMO:0000009 mean arterial blood pressure 116 mmHg 1.0 2.6458 MMO:0000577 intra-aortic radiotelemetry 0.0 controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) 99189 controlled sodium content diet (8 %) (for 8 days) 0.9% sodium chloride solution (0.9 %) (for 8 days) vehicle control condition (0.5 ml) (for 8 days) 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricular blood pressure trait RS:0000811 SS/JrHsdMcwi male 56 days 6 CMO:0003281 right ventricular end-systolic blood pressure 26 mmHg 0.99 2.425 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106796 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricular blood pressure trait RS:0001480 SS-Sod3m1Mcwi male 56 days 15 CMO:0003281 right ventricular end-systolic blood pressure 25.1 mmHg 0.53 2.0527 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106797 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. body mass RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000012 body weight 425 g 22.0 58.2065 MMO:0000016 body weighing method 0.0 vehicle control condition 99758 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. body mass RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000012 body weight 452 g 21.0 55.5608 MMO:0000016 body weighing method 0.0 vehicle control condition 99760 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0002791 heart interventricular end-diastolic septal wall thickness 2.01 mm 0.08 0.2117 MMO:0000337 echocardiography 0.0 vehicle control condition 99762 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0002791 heart interventricular end-diastolic septal wall thickness 1.92 mm 0.12 0.3175 MMO:0000337 echocardiography 0.0 vehicle control condition 99764 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0002791 heart interventricular end-diastolic septal wall thickness 2.26 mm 0.23 0.6085 MMO:0000337 echocardiography 0.0 vehicle control condition 99766 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0002597 heart left ventricle end-diastolic posterior wall thickness 1.89 mm 0.16 0.4233 MMO:0000337 echocardiography 0.0 vehicle control condition 99776 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle posterior wall thickness RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0002597 heart left ventricle end-diastolic posterior wall thickness 2.17 mm 1.94 5.1328 MMO:0000337 echocardiography 0.0 vehicle control condition 99778 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0002792 heart interventricular end-systolic septal wall thickness 3.19 mm 0.2 0.5292 MMO:0000337 echocardiography 0.0 vehicle control condition 99780 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0002792 heart interventricular end-systolic septal wall thickness 3.24 mm 0.21 0.5556 MMO:0000337 echocardiography 0.0 vehicle control condition 99782 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart ventricle septum thickness RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0002792 heart interventricular end-systolic septal wall thickness 3.48 mm 0.26 0.6879 MMO:0000337 echocardiography 0.0 vehicle control condition 99784 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-systolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 84 days 7 CMO:0000983 heart left ventricle end-systolic diameter 3.98 mm 0.45 1.1906 MMO:0000337 echocardiography 0.0 vehicle control condition 99786 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-systolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 168 days 7 CMO:0000983 heart left ventricle end-systolic diameter 4.83 mm 0.35 0.926 MMO:0000337 echocardiography 0.0 vehicle control condition 99788 vehicle control condition 2319 Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. heart left ventricle end-systolic diameter RS:0003075 SS-Nppbem2Mcwi-/- male 252 days 7 CMO:0000983 heart left ventricle end-systolic diameter 4.67 mm 0.74 1.9579 MMO:0000337 echocardiography 0.0 vehicle control condition 99790 vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. body mass RS:0000592 MW male 0 days 7 CMO:0000012 body weight 220 g 9.0 23.8118 MMO:0000119 body measuring method 0.0 unx 14 days unilateral nephrectomy (for 14 days) then vehicle control condition 101142 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. body mass RS:0000592 MW male 0 days 7 CMO:0000012 body weight 260 g 6.0 15.8745 MMO:0000119 body measuring method 0.0 unx 42 days unilateral nephrectomy (for 14 days) then vehicle control condition 101146 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. body mass RS:0000592 MW male 0 days 7 CMO:0000012 body weight 286 g 9.0 23.8118 MMO:0000119 body measuring method 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101154 unilateral nephrectomy (for 70 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. arterial blood pressure trait RS:0000592 MW male 0 days 7 CMO:0000004 systolic blood pressure undefined 118 mmHg 2.0 5.2915 MMO:0000031 tail cuff plethysmography 0.0 unx 14 days unilateral nephrectomy (for 14 days) then vehicle control condition 101159 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. arterial blood pressure trait RS:0000592 MW male 0 days 7 CMO:0000004 systolic blood pressure undefined 118 mmHg 2.0 5.2915 MMO:0000031 tail cuff plethysmography 0.0 unx 42 days unilateral nephrectomy (for 14 days) then vehicle control condition 101163 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. arterial blood pressure trait RS:0000592 MW male 0 days 7 CMO:0000004 systolic blood pressure undefined 122 mmHg 2.0 5.2915 MMO:0000031 tail cuff plethysmography 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101168 unilateral nephrectomy (for 70 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. arterial blood pressure trait RS:0000592 MW male 0 days 7 CMO:0000009 mean arterial blood pressure undefined 108 mmHg 2.0 5.2915 MMO:0000011 vascular indwelling catheter method 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101173 unilateral nephrectomy (for 70 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. blood urea nitrogen amount RS:0000592 MW male 0 days 7 CMO:0000049 blood urea nitrogen level 25 mg/dl 1.0 2.6458 MMO:0000253 blood urea nitrogen analysis 0.0 unx 14 days unilateral nephrectomy (for 14 days) then vehicle control condition 101178 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. blood urea nitrogen amount RS:0000592 MW male 0 days 7 CMO:0000049 blood urea nitrogen level 25 mg/dl 3.0 7.9373 MMO:0000253 blood urea nitrogen analysis 0.0 unx 42 days unilateral nephrectomy (for 14 days) then vehicle control condition 101182 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. blood urea nitrogen amount RS:0000592 MW male 0 days 7 CMO:0000049 blood urea nitrogen level 26 mg/dl 1.0 2.6458 MMO:0000253 blood urea nitrogen analysis 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101187 unilateral nephrectomy (for 70 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. total urine protein amount RS:0000592 MW male 0 days 7 CMO:0000756 urine total protein excretion rate 11 mg/d 2.0 5.2915 MMO:0000426 Bradford protein assay 0.0 unx 14 days unilateral nephrectomy (for 14 days) then vehicle control condition 101192 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. total urine protein amount RS:0000592 MW male 0 days 7 CMO:0000756 urine total protein excretion rate 23 mg/d 2.0 5.2915 MMO:0000426 Bradford protein assay 0.0 unx 42 days unilateral nephrectomy (for 14 days) then vehicle control condition 101196 unilateral nephrectomy (for 14 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. total urine protein amount RS:0000592 MW male 0 days 7 CMO:0000756 urine total protein excretion rate 18 mg/d 4.0 10.583 MMO:0000426 Bradford protein assay 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101200 unilateral nephrectomy (for 70 days) vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. total urine protein amount RS:0000592 MW male 0 days 18 CMO:0000756 urine total protein excretion rate 8 mg/d 2.0 8.4853 MMO:0000426 Bradford protein assay 0.0 control 29 days vehicle control condition 101203 vehicle control condition 2581 Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30. glomerular filtration trait RS:0000592 MW male 0 days 7 CMO:0000490 glomerular filtration rate 1.46 ml/min 0.08 0.2117 MMO:0000634 inulin analysis by liquid phase colorimetry 0.0 unx 70 days unilateral nephrectomy (for 70 days) then vehicle control condition 101205 unilateral nephrectomy (for 70 days) vehicle control condition 2583 Kohara K, et al., Hypertension. 1993 Jun;21(6 Pt 2):975-9. blood sodium amount RS:0000752 SHR/NCrlCrlj male 126 days 5 CMO:0000499 blood sodium level 140 mmol/l 1.0 2.2361 MMO:0000142 automated serum sodium test 0.0 unx 42 days unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) 101238 unilateral nephrectomy (for 42 days) vehicle control condition (for 28 days) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000009 mean arterial blood pressure undefined 138 mmHg 9.0 22.0454 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103015 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 128 mmHg 9.0 23.8118 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103016 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 5 CMO:0000009 mean arterial blood pressure undefined 137 mmHg 6.0 13.4164 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103017 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 147 mmHg 7.0 18.5203 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103018 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000009 mean arterial blood pressure undefined 90 mmHg 8.0 19.5959 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103019 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 96 mmHg 8.0 21.166 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103020 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 5 CMO:0000009 mean arterial blood pressure undefined 108 mmHg 8.0 17.8885 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103021 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 111 mmHg 5.0 13.2288 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103022 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000009 mean arterial blood pressure undefined 99 mmHg 7.0 17.1464 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103023 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 109 mmHg 10.0 26.4575 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103024 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 123 mmHg 5.0 13.2288 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103026 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000009 mean arterial blood pressure undefined 155 mmHg 10.0 24.4949 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours) 103027 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 136 mmHg 13.0 34.3948 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103028 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 5 CMO:0000009 mean arterial blood pressure undefined 151 mmHg 1.0 2.2361 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103029 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 140 mmHg 8.0 21.166 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103030 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000009 mean arterial blood pressure undefined 120 mmHg 7.0 17.1464 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103031 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 102 mmHg 11.0 29.1033 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103032 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 5 CMO:0000009 mean arterial blood pressure undefined 137 mmHg 3.0 6.7082 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103033 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 7 CMO:0000009 mean arterial blood pressure undefined 143 mmHg 3.0 7.9373 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103034 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000002 heart rate 372 beats/min 11.0 26.9444 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103035 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 415 beats/min 10.0 26.4575 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103036 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 5 CMO:0000002 heart rate 395 beats/min 17.0 38.0132 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103037 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 7 CMO:0000002 heart rate 147 beats/min 7.0 18.5203 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) 103038 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000002 heart rate 90 beats/min 15.0 36.7423 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103039 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 380 beats/min 18.0 47.6235 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103040 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 5 CMO:0000002 heart rate 366 beats/min 17.0 38.0132 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103041 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 379 beats/min 9.0 23.8118 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103042 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000002 heart rate 351 beats/min 19.0 46.5403 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103043 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 384 beats/min 17.0 44.9778 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103044 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 5 CMO:0000002 heart rate 366 beats/min 17.0 38.0132 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103045 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 7 CMO:0000002 heart rate 390 beats/min 10.0 26.4575 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103046 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000002 heart rate 288 beats/min 11.0 26.9444 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours) 103047 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 287 beats/min 7.0 18.5203 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103048 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 5 CMO:0000002 heart rate 301 beats/min 21.0 46.9574 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103049 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 7 CMO:0000002 heart rate 344 beats/min 11.0 29.1033 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) 103050 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 6 CMO:0000002 heart rate 275 beats/min 8.0 19.5959 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103051 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001840 Crlj:WI male 16 days 7 CMO:0000002 heart rate 264 beats/min 9.0 23.8118 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103052 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 5 CMO:0000002 heart rate 252 beats/min 25.0 55.9017 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103053 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. heart pumping trait RS:0001299 GK male 16 days 7 CMO:0000002 heart rate 279 beats/min 17.0 44.9778 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) 103054 air oxygen content (5 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) meclofenamate (3 mg/kg) (for 0.5 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait RS:0001299 GK male 168 days 6 CMO:0000002 heart rate nighttime measurement 323 beats/min 8.0 19.5959 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103568 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. voluntary movement trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0003644 number of spontaneous locomotor movements per unit time number of spontaneous locomotor movements per unit time (CMO:0003644) 0.9 /min 0.1 0.2449 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103574 vehicle control condition (between 1 and 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. voluntary movement trait RS:0001299 GK male 168 days 6 CMO:0003644 number of spontaneous locomotor movements per unit time number of spontaneous locomotor movements per unit time (CMO:0003644) 0.9 /min 0.1 0.2449 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103576 vehicle control condition (between 1 and 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. voluntary movement trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0003644 number of spontaneous locomotor movements per unit time number of spontaneous locomotor movements per unit time (CMO:0003644) 2.8 /min 0.3 0.7348 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle 103582 vehicle control condition (between 1 and 28 days) dark phase of controlled light/dark cycle 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. voluntary movement trait RS:0001299 GK male 168 days 6 CMO:0003644 number of spontaneous locomotor movements per unit time number of spontaneous locomotor movements per unit time (CMO:0003644) 2.9 /min 0.1 0.2449 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle 103584 vehicle control condition (between 1 and 28 days) dark phase of controlled light/dark cycle 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000725 logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -7.07 0.054 0.1429 MMO:0000342 wire myography vehicle control condition (for 28 days) 103586 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000725 logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -7.29 0.092 0.2602 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103588 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 89.88 % 2.56 6.7731 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103590 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 67.1 % 3.32 9.3904 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103592 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000727 logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -8.058 0.048 0.127 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103594 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000727 logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -7.96 0.048 0.1358 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103596 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000732 sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 97.56 % 1.02 2.6987 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103598 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000732 sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 94.07 % 1.125 3.182 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103600 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000725 logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -7.6 0.05 0.1323 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103602 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000725 logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -7.39 0.04 0.1131 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103604 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 99.75 % 2.32 6.1381 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103606 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 96.96 % 2.2 6.2225 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103608 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000727 logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -8.15 0.089 0.2355 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103610 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000727 logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) -8.74 0.57 1.6122 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103612 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0000731 WKY/NCrl male 168 days 7 CMO:0000732 sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 96.54 % 1.9 5.0269 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103614 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait RS:0001299 GK male 168 days 8 CMO:0000732 sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 86.87 % 3.06 8.655 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 103616 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait RS:0000731 WKY/NCrl male 175 days 7 CMO:0002853 aorta wall phosphorylated eNOS level to total eNOS level ratio 1.45 0.21 0.5556 MMO:0000669 western blot assay 0.0 vehicle control condition (for 35 days) 103618 vehicle control condition (for 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait RS:0001299 GK male 175 days 8 CMO:0002853 aorta wall phosphorylated eNOS level to total eNOS level ratio 1.61 0.3 0.8485 MMO:0000669 western blot assay 0.0 vehicle control condition (for 35 days) 103620 vehicle control condition (for 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait RS:0000731 WKY/NCrl male 175 days 7 CMO:0002852 mesenteric artery phosphorylated eNOS level to total eNOS level ratio 0.94 0.13 0.3439 MMO:0000669 western blot assay 0.0 vehicle control condition (for 35 days) 103622 vehicle control condition (for 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait RS:0001299 GK male 175 days 8 CMO:0002852 mesenteric artery phosphorylated eNOS level to total eNOS level ratio 0.9 0.07 0.198 MMO:0000669 western blot assay 0.0 vehicle control condition (for 35 days) 103624 vehicle control condition (for 35 days) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood glucose amount RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000046 blood glucose level 65 mg/dl 1.0 3.6056 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) 102656 vehicle control condition fasting (for 16 hours) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood glucose amount RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000046 blood glucose level 67 mg/dl 1.0 2.8284 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) 102657 vehicle control condition fasting (for 16 hours) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood glucose amount RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000046 blood glucose level 132 mg/dl 4.0 14.4222 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) 102659 vehicle control condition fasting (for 16 hours) glucose (2 g/kg) (for 1 hours) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood glucose amount RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000046 blood glucose level 121 mg/dl 6.0 16.9706 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) 102660 vehicle control condition fasting (for 16 hours) glucose (2 g/kg) (for 1 hours) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood cholesterol amount RS:0001366 LL/Mav male 112 days 13 CMO:0000585 plasma total cholesterol level 50.5791 mg/dl 2.7027 9.7447 MMO:0000491 blood cholesterol analysis 0.0 vehicle control condition 102662 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood cholesterol amount RS:0000556 LH/Mav male 112 days 8 CMO:0000585 plasma total cholesterol level 66.4092 mg/dl 5.4054 15.2888 MMO:0000491 blood cholesterol analysis 0.0 vehicle control condition 102663 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood triglyceride amount RS:0001366 LL/Mav male 112 days 13 CMO:0000548 plasma triglyceride level 1.58 mmol/l 0.13 0.4687 MMO:0000234 plasma triglyceride analysis 0.0 vehicle control condition 102668 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood triglyceride amount RS:0000556 LH/Mav male 112 days 8 CMO:0000548 plasma triglyceride level 1.57 mmol/l 0.06 0.1697 MMO:0000234 plasma triglyceride analysis 0.0 vehicle control condition 102669 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood creatinine amount RS:0001366 LL/Mav male 112 days 13 CMO:0000537 plasma creatinine level 0.518 mg/dl 0.01 0.0361 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102674 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. blood creatinine amount RS:0000554 LH/MavRrrc male 112 days 8 CMO:0000537 plasma creatinine level 0.53 mg/dl 0.012 0.0339 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102675 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. heart left ventricle mass RS:0001366 LL/Mav male 112 days 13 CMO:0000530 heart left ventricle weight to body weight ratio 20.4 mg/g 0.1 0.3606 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102680 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. heart left ventricle mass RS:0000554 LH/MavRrrc male 112 days 8 CMO:0000530 heart left ventricle weight to body weight ratio 23 mg/g 0.2 0.5657 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102681 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. aorta mass RS:0001366 LL/Mav male 112 days 13 CMO:0003216 aorta weight to body weight ratio 11.6 mg/100g 0.3 1.0817 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102686 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. aorta mass RS:0000554 LH/MavRrrc male 112 days 8 CMO:0003216 aorta weight to body weight ratio 12.2 mg/100g 0.2 0.5657 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102687 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. kidney mass RS:0001366 LL/Mav male 112 days 13 CMO:0000340 both kidneys wet weight to body weight ratio 6.53 g/kg 0.04 0.1442 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102692 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. kidney mass RS:0000554 LH/MavRrrc male 112 days 8 CMO:0000340 both kidneys wet weight to body weight ratio 6.36 g/kg 0.08 0.2263 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102693 vehicle control condition 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. arterial blood pressure trait RS:0004500 SD-Nfe2l2em1Mcwi+/+ male 11 days to 9 days 4 CMO:0000009 mean arterial blood pressure 95 mmHg 3.9 7.8 MMO:0000013 vascular fluid filled catheter 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) 100739 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. arterial blood pressure trait RS:0004501 SD-Nfe2l2em1Mcwi-/- male 11 days to 9 days 3 CMO:0000009 mean arterial blood pressure 102 mmHg 3.0 5.1962 MMO:0000013 vascular fluid filled catheter 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) 100740 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004500 SD-Nfe2l2em1Mcwi+/+ male 11 days to 9 days 5 CMO:0001128 middle cerebral artery inner diameter max dilation 246 um 4.8 10.7331 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) 100745 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) controlled calcium ion content physiological salt solution perfusate (0 %) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004501 SD-Nfe2l2em1Mcwi-/- male 11 days to 9 days 4 CMO:0001128 middle cerebral artery inner diameter max dilation 248 um 9.0 18.0 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) 100746 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) controlled calcium ion content physiological salt solution perfusate (0 %) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004500 SD-Nfe2l2em1Mcwi+/+ male 11 days to 9 days 5 CMO:0001128 middle cerebral artery inner diameter resting diameter 145 um 12.5 27.9508 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate 100751 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) physiological salt solution perfusate 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004501 SD-Nfe2l2em1Mcwi-/- male 11 days to 9 days 4 CMO:0001128 middle cerebral artery inner diameter resting diameter 154 um 15.0 30.0 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate 100752 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) physiological salt solution perfusate 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004500 SD-Nfe2l2em1Mcwi+/+ male 11 days to 9 days 5 CMO:0001190 percent change in middle cerebral artery inner diameter tone 41.4 % 4.47 9.9952 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate 100757 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) physiological salt solution perfusate 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. cerebral artery size trait RS:0004501 SD-Nfe2l2em1Mcwi-/- male 11 days to 9 days 4 CMO:0001190 percent change in middle cerebral artery inner diameter tone 37.4 % 6.53 13.06 MMO:0000027 ex vivo method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate 100758 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) physiological salt solution perfusate 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood cholesterol amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000363 serum total cholesterol level 333 mg/dl 15.6 38.212 MMO:0000132 serum total cholesterol measurement test 0.0 vehicle control condition (0.5 %) (for 28 days) 101941 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood LDL cholesterol amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000362 serum low density lipoprotein cholesterol level 102.5 mg/dl 9.37 22.9517 MMO:0000134 serum low-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (0.5 %) (for 28 days) 101944 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood HDL cholesterol amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000361 serum high density lipoprotein cholesterol level 97.25 mg/dl 15.33 37.5507 MMO:0000133 serum high-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (0.5 %) (for 28 days) 101947 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood triglyceride amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000360 serum triglyceride level 2196.13 mg/dl 204.52 500.9696 MMO:0000136 serum triglyceride analysis 0.0 vehicle control condition (0.5 %) (for 28 days) 101950 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood free fatty acid amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000547 serum free fatty acids level 1.42 mmol/l 0.14 0.3429 MMO:0000308 serum free fatty acid analysis 0.0 vehicle control condition (0.5 %) (for 28 days) 101953 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood glucose amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000543 serum glucose level 149.4 mg/dl 12.36 30.2757 MMO:0000316 serum glucose analysis 0.0 vehicle control condition (0.5 %) (for 28 days) 101956 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood insulin amount RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 6 CMO:0000358 serum insulin level 0.000807 mg/dl 1.0E-4 2.0E-4 MMO:0000322 serum insulin analysis 0.0 vehicle control condition (0.5 %) (for 28 days) 101959 vehicle control condition (0.5 %) (for 28 days) 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. body mass RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000012 body weight 219 g 5.0 18.0278 MMO:0000016 body weighing method 0.0 vehicle control condition 102641 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. body mass RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000012 body weight 232 g 6.0 16.9706 MMO:0000016 body weighing method 0.0 vehicle control condition 102642 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. arterial blood pressure trait RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000004 systolic blood pressure undefined 115 mmHg 3.0 10.8167 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102644 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. arterial blood pressure trait RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000004 systolic blood pressure undefined 136 mmHg 3.0 8.4853 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102645 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. urine output RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000260 timed urine volume 8.4 ml/d 0.3 1.0817 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102647 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. urine output RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000260 timed urine volume 8.7 ml/d 0.6 1.6971 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102648 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. urine creatinine amount RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0000764 urine creatinine excretion rate 7.1 mg/d 0.3 1.0817 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition 102650 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. urine creatinine amount RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0000764 urine creatinine excretion rate 8 mg/d 0.3 0.8485 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition 102651 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. total urine protein amount RS:0001366 LL/Mav male 56 days to 49 days 13 CMO:0002758 urine protein level to urine creatinine level ratio 2.7 0.1 0.3606 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102653 vehicle control condition 2703 Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. total urine protein amount RS:0000556 LH/Mav male 56 days to 49 days 8 CMO:0002758 urine protein level to urine creatinine level ratio 5.9 0.5 1.4142 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102654 vehicle control condition 2541 Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. body mass RS:0003240 MWF/ZtmRrrc male 126 days 8 CMO:0000012 body weight 378 g 10.6066 30.0 MMO:0000016 body weighing method 0.0 vehicle control condition 100901 vehicle control condition 2541 Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. body mass RS:0003240 MWF/ZtmRrrc male 126 days 7 CMO:0000012 body weight 385 g 11.3389 30.0 MMO:0000016 body weighing method 0.0 vehicle control condition 100903 vehicle control condition 2541 Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. body mass RS:0003240 MWF/ZtmRrrc male 246 days 8 CMO:0000012 body weight 433 g 9.1924 26.0 MMO:0000016 body weighing method 0.0 vehicle control condition 100905 vehicle control condition 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. tibia length RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0001731 tibia straight segment length 34.62 mm 0.15 0.5408 MMO:0000119 body measuring method 0.0 vehicle control condition (0.5 %) (for 28 days) 101971 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0001198 heart weight to tibia length ratio 0.4295 g/cm 0.0115 0.0415 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101974 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0002787 heart left ventricle weight to tibia length ratio lv/tl 0.3101 g/cm 0.009 0.0324 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101977 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. retroperitoneal fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0002990 retroperitoneal fat pad weight to tibia length ratio rf/tl 429.56 mg/mm 13.64 49.1797 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101980 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. epididymal fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0001201 epididymal fat pad weight to tibia length ratio ef/tl 3.5481 g/cm 0.0975 0.3515 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101983 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. mesenteric fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0003286 mesenteric fat pad weight to tibia length ratio mf/tl 364.22 mg/mm 10.33 37.2453 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101986 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. inguinal fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0002991 inguinal fat pad weight to tibia length ratio if/tl 1501.32 mg/mm 68.53 247.0884 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (0.5 %) (for 28 days) 101989 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000987 heart ventricle septal wall thickness 0.206 cm 0.003 0.0108 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 101992 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000982 heart left ventricle end-diastolic diameter 8.27 mm 0.13 0.4687 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 101995 vehicle control condition (0.5 %) (for 28 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. body mass RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000012 body weight 361 g 9.0 25.4558 MMO:0000016 body weighing method 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102311 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. arterial blood pressure trait RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000004 systolic blood pressure undefined 226 mmHg 11.0 31.1127 MMO:0000031 tail cuff plethysmography 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102314 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. heart left ventricle end-diastolic diameter RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000985 heart left ventricle fractional shortening 24.8 % 1.2 3.3941 MMO:0000002 transthoracic echocardiography 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102317 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000004 systolic blood pressure daytime measurement 121 mmHg 3.0 7.3485 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103526 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0001299 GK male 168 days 6 CMO:0000004 systolic blood pressure daytime measurement 145 mmHg 4.0 9.798 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103528 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000004 systolic blood pressure nighttime measurement 126 mmHg 3.0 7.3485 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103534 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0001299 GK male 168 days 6 CMO:0000004 systolic blood pressure nighttime measurement 145 mmHg 4.0 9.798 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103536 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000005 diastolic blood pressure daytime measurement 85 mmHg 3.0 7.3485 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103542 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0001299 GK male 168 days 6 CMO:0000005 diastolic blood pressure daytime measurement 98 mmHg 2.0 4.899 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103544 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0001013 WI male 547 days 4 CMO:0002832 neuron mitochondrion area to neuron cytoplasm area ratio mito/cyto 10.4 % 0.16 0.32 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103644 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0000634 OXYS/Nov male 547 days 4 CMO:0002832 neuron mitochondrion area to neuron cytoplasm area ratio mito/cyto 3.6 % 0.1 0.2 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103645 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0001013 WI male 547 days 4 CMO:0002836 neuron lysosome area to neuron cytoplasm area ratio lys/cyto 8.3 % 0.19 0.38 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103647 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0000634 OXYS/Nov male 547 days 4 CMO:0002836 neuron lysosome area to neuron cytoplasm area ratio lys/cyto 11.9 % 0.39 0.78 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103648 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0001013 WI male 547 days 4 CMO:0002840 neuron golgi apparatus area to neuron cytoplasm area ratio ga/cyto 1.05 % 0.04 0.08 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103650 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0000634 OXYS/Nov male 547 days 4 CMO:0002840 neuron golgi apparatus area to neuron cytoplasm area ratio ga/cyto 1.2 % 0.04 0.08 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103651 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0001013 WI male 547 days 4 CMO:0002844 neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio rer/cyto 27.4 % 0.51 1.02 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103653 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0000634 OXYS/Nov male 547 days 4 CMO:0002844 neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio rer/cyto 11.2 % 0.33 0.66 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103654 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0001013 WI male 547 days 4 CMO:0002848 neuron vacuole area to neuron cytoplasm area ratio v/cyto 3.97 % 0.34 0.68 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103656 vehicle control condition (for 180 days) 2844 Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8. neuron morphology trait RS:0000634 OXYS/Nov male 547 days 4 CMO:0002848 neuron vacuole area to neuron cytoplasm area ratio v/cyto 8.23 % 0.4 0.8 MMO:0000221 ex vivo electron microscopy with digital image analysis 0.0 vehicle control condition (for 180 days) 103657 vehicle control condition (for 180 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0000760 SHRSP/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 4.66 g/kg 0.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102100 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0000761 WKY/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 3.48 g/kg 0.26 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102101 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 4.03 g/kg 0.28 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102102 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004553 SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc male 126 days 6 CMO:0000074 heart weight to body weight ratio 4.47 g/kg 0.27 0.6614 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102103 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004554 SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 3.88 g/kg 0.12 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102104 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004555 SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc male 126 days 7 CMO:0000074 heart weight to body weight ratio 4.07 g/kg 0.17 0.4498 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102105 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 4.26 g/kg 0.3 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102106 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004557 SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 4.72 g/kg 0.64 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102107 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0002926 urine urea level to urine creatinine level ratio 112.69 29.95 123.487 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 103791 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0000761 WKY/Gcrc male 126 days 18 CMO:0002926 urine urea level to urine creatinine level ratio 68.85 9.11 38.6505 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 103792 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0002926 urine urea level to urine creatinine level ratio 87.33 12.81 38.43 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 103793 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0002926 urine urea level to urine creatinine level ratio 101.15 8.47 22.4095 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 103794 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0002926 urine urea level to urine creatinine level ratio 76.34 4.14 10.1409 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 103795 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart mass RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days N/A CMO:0000074 heart weight to body weight ratio 4.67 g/kg 0.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102108 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0000760 SHRSP/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 3.64 mg/g 0.39 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102109 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0000761 WKY/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 2.52 mg/g 0.2 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102110 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 3.04 mg/g 0.29 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102111 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004553 SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc male 126 days 6 CMO:0000530 heart left ventricle weight to body weight ratio 3.33 mg/g 0.33 0.8083 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102112 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004554 SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 2.79 mg/g 0.14 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102113 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004555 SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc male 126 days 7 CMO:0000530 heart left ventricle weight to body weight ratio 3 mg/g 0.11 0.291 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102114 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 3.12 mg/g 0.24 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102115 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004557 SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 3.57 mg/g 0.66 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102116 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. heart left ventricle mass RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days N/A CMO:0000530 heart left ventricle weight to body weight ratio 3.28 mg/g 0.19 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102117 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0000760 SHRSP/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 4.11 g/kg 0.25 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102118 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0000761 WKY/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 2.87 g/kg 0.23 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102119 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 3.65 g/kg 0.2 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102120 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004553 SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc male 126 days 6 CMO:0000340 both kidneys wet weight to body weight ratio 3.78 g/kg 0.18 0.4409 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102121 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004554 SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 3.77 g/kg 0.12 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102122 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 4.16 g/kg 0.4 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102123 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood albumin amount RS:0002216 Slc:W male 105 days N/A CMO:0002898 blood glycated albumin level glycated albumin n=4-6 1.5 % 0.05 MMO:0000166 blood protein analysis 0.0 vehicle control condition (for 21 days) 102874 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood albumin amount RS:0000482 GK/Slc male 105 days N/A CMO:0002898 blood glycated albumin level glycated albumin n=4-6 2.3 % 0.07 MMO:0000166 blood protein analysis 0.0 vehicle control condition (for 21 days) 102876 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood hemoglobin amount RS:0002216 Slc:W male 105 days N/A CMO:0002786 blood hemoglobin A1c level HbA1c n=4-6 5.32 % 0.13 MMO:0000295 blood hemoglobin analysis 0.0 vehicle control condition (for 21 days) 102878 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood hemoglobin amount RS:0000482 GK/Slc male 105 days N/A CMO:0002786 blood hemoglobin A1c level HbA1c n=4-6 5.21 % 0.12 MMO:0000295 blood hemoglobin analysis 0.0 vehicle control condition (for 21 days) 102880 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood free fatty acid amount RS:0002216 Slc:W male 105 days N/A CMO:0000117 blood free fatty acids level ueq/l = umol/l 9.99485 mg/dl 0.7204 MMO:0000216 blood free fatty acid analysis 0.0 vehicle control condition (for 21 days) 102882 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood free fatty acid amount RS:0000482 GK/Slc male 105 days N/A CMO:0000117 blood free fatty acids level ueq/l = umol/l 12.551475 mg/dl 0.517 MMO:0000216 blood free fatty acid analysis 0.0 vehicle control condition (for 21 days) 102884 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood triglyceride amount RS:0002216 Slc:W male 105 days N/A CMO:0000118 blood triglyceride level n=4-6 119.5 mg/dl 12.4 MMO:0000233 blood triglyceride analysis 0.0 vehicle control condition (for 21 days) 102886 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood triglyceride amount RS:0000482 GK/Slc male 105 days N/A CMO:0000118 blood triglyceride level n=4-6 52.3 mg/dl 7.4 MMO:0000233 blood triglyceride analysis 0.0 vehicle control condition (for 21 days) 102888 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood cholesterol amount RS:0002216 Slc:W male 105 days N/A CMO:0000051 blood total cholesterol level n=4-6 67 mg/dl 3.5 MMO:0000491 blood cholesterol analysis 0.0 vehicle control condition (for 21 days) 102890 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood cholesterol amount RS:0000482 GK/Slc male 105 days N/A CMO:0000051 blood total cholesterol level n=4-6 77.8 mg/dl 5.2 MMO:0000491 blood cholesterol analysis 0.0 vehicle control condition (for 21 days) 102892 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood HDL cholesterol amount RS:0002216 Slc:W male 105 days N/A CMO:0000052 blood high density lipoprotein cholesterol level n=4-6 4.2 mg/dl 0.3 MMO:0000278 blood high-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (for 21 days) 102894 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood HDL cholesterol amount RS:0000482 GK/Slc male 105 days N/A CMO:0000052 blood high density lipoprotein cholesterol level n=4-6 9 mg/dl 0.9 MMO:0000278 blood high-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (for 21 days) 102896 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood LDL cholesterol amount RS:0002216 Slc:W male 105 days N/A CMO:0000053 blood low density lipoprotein cholesterol level n=4-6 26.8 mg/dl 1.4 MMO:0000279 blood low-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (for 21 days) 102898 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood LDL cholesterol amount RS:0000482 GK/Slc male 105 days N/A CMO:0000053 blood low density lipoprotein cholesterol level n=4-6 24.3 mg/dl 1.8 MMO:0000279 blood low-density lipoprotein-cholesterol measurement test 0.0 vehicle control condition (for 21 days) 102900 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood urea nitrogen amount RS:0002216 Slc:W male 105 days N/A CMO:0000049 blood urea nitrogen level n=4-6 19.8 mg/dl 0.6 MMO:0000253 blood urea nitrogen analysis 0.0 vehicle control condition (for 21 days) 102902 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood urea nitrogen amount RS:0000482 GK/Slc male 105 days N/A CMO:0000049 blood urea nitrogen level n=4-6 15.7 mg/dl 1.2 MMO:0000253 blood urea nitrogen analysis 0.0 vehicle control condition (for 21 days) 102904 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood creatinine amount RS:0002216 Slc:W male 105 days N/A CMO:0000538 blood creatinine level n=4-6 0.33 mg/dl 0.01 MMO:0000270 blood creatinine analysis 0.0 vehicle control condition (for 21 days) 102906 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. blood creatinine amount RS:0000482 GK/Slc male 105 days N/A CMO:0000538 blood creatinine level n=4-6 0.26 mg/dl 0.02 MMO:0000270 blood creatinine analysis 0.0 vehicle control condition (for 21 days) 102908 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine ketone body amount RS:0002216 Slc:W male 105 days N/A CMO:0002897 urine acetoacetone level n=4-6 50.3 umol/l 2.6 MMO:0000147 urine analysis 0.0 vehicle control condition (for 21 days) 102914 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine ketone body amount RS:0000482 GK/Slc male 105 days N/A CMO:0002897 urine acetoacetone level n=4-6 91.5 umol/l 39.9 MMO:0000147 urine analysis 0.0 vehicle control condition (for 21 days) 102916 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine ketone body amount RS:0002216 Slc:W male 105 days N/A CMO:0002896 urine 3-hydroxybutyrate level n=4-6 265.3 umol/l 11.7 MMO:0000147 urine analysis 0.0 vehicle control condition (for 21 days) 102918 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine ketone body amount RS:0000482 GK/Slc male 105 days N/A CMO:0002896 urine 3-hydroxybutyrate level n=4-6 323.3 umol/l 92.7 MMO:0000147 urine analysis 0.0 vehicle control condition (for 21 days) 102920 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine output RS:0002216 Slc:W male 105 days N/A CMO:0000260 timed urine volume n=4-6 11.2 ml/d 0.5 MMO:0000357 urine volume measurement method 0.0 vehicle control condition (for 21 days) 102922 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine output RS:0000482 GK/Slc male 105 days N/A CMO:0000260 timed urine volume n=4-6 9.6 ml/d 0.7 MMO:0000357 urine volume measurement method 0.0 vehicle control condition (for 21 days) 102924 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine glucose amount RS:0002216 Slc:W male 105 days N/A CMO:0000383 urine glucose level n=4-6 31.8 mg/dl 3.4 MMO:0000165 blood glucose test strip read by electrochemical glucometer 0.0 vehicle control condition (for 21 days) 102926 vehicle control condition (for 21 days) 2781 Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y. urine glucose amount RS:0000482 GK/Slc male 105 days N/A CMO:0000383 urine glucose level n=4-6 588.3 mg/dl 349.4 MMO:0000165 blood glucose test strip read by electrochemical glucometer 0.0 vehicle control condition (for 21 days) 102928 vehicle control condition (for 21 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000005 diastolic blood pressure nighttime measurement 89 mmHg 3.0 7.3485 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103550 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait RS:0001299 GK male 168 days 6 CMO:0000005 diastolic blood pressure nighttime measurement 104 mmHg 2.0 4.899 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103552 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000002 heart rate daytime measurement 294 beats/min 5.0 12.2474 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103558 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait RS:0001299 GK male 168 days 6 CMO:0000002 heart rate daytime measurement 279 beats/min 3.0 7.3485 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) 103560 vehicle control condition (for 28 days) light phase of controlled light/dark cycle (for 12 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait RS:0000731 WKY/NCrl male 168 days 6 CMO:0000002 heart rate nighttime measurement 344 beats/min 5.0 12.2474 MMO:0000070 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) 103566 vehicle control condition (for 28 days) dark phase of controlled light/dark cycle (for 12 hours) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002787 heart left ventricle weight to tibia length ratio lv/tl 0.2 g/cm 0.005 0.015 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101695 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002787 heart left ventricle weight to tibia length ratio lv/tl 0.28 g/cm 0.007 0.0198 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101697 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002990 retroperitoneal fat pad weight to tibia length ratio vf/tl 105 mg/mm 9.0 27.0 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101699 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002990 retroperitoneal fat pad weight to tibia length ratio vf/tl 482 mg/mm 18.0 50.9117 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101701 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002991 inguinal fat pad weight to tibia length ratio sf/tl 32 mg/mm 3.0 9.0 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101703 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002991 inguinal fat pad weight to tibia length ratio sf/tl 209 mg/mm 12.0 33.9411 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101705 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000987 heart ventricle septal wall thickness 0.158 cm 0.003 0.009 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101707 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000987 heart ventricle septal wall thickness 0.205 cm 0.004 0.0113 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101709 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass RS:0000742 WKY male 252 days to 238 days 15 CMO:0000082 right kidney wet weight 1.3533 g 0.0439 0.17 MMO:0000005 post excision weight measurement 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100373 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output RS:0000742 WKY male 252 days to 238 days 7 CMO:0000260 timed urine volume 10.6 ml/d 2.2 5.8207 MMO:0000357 urine volume measurement method 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100376 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount RS:0000742 WKY male 252 days to 238 days 6 CMO:0000537 plasma creatinine level 0.52 mg/dl 0.04 0.098 MMO:0000306 plasma creatinine analysis 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100379 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney integrity trait RS:0000742 WKY male 252 days to 238 days 15 CMO:0001258 kidney fibrotic lesion area to total kidney area ratio 0.75 % 0.13 0.5035 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100385 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney blood vessel morphology trait RS:0000742 WKY male 252 days to 238 days 15 CMO:0002790 artery tunica media width to artery inner diameter ratio 1.82 0.15 0.5809 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100388 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000012 body weight 294 g 6.0 18.0 MMO:0000016 body weighing method 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101661 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000012 body weight 393 g 6.0 16.9706 MMO:0000016 body weighing method 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101663 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0001731 tibia straight segment length 35.8 mm 0.4 1.2 MMO:0000209 body length measuring method 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101665 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0001731 tibia straight segment length 32.5 mm 0.9 2.5456 MMO:0000209 body length measuring method 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101667 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000004 systolic blood pressure undefined 138 mmHg 1.0 3.0 MMO:0000031 tail cuff plethysmography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101669 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000004 systolic blood pressure undefined 221 mmHg 5.0 14.1421 MMO:0000031 tail cuff plethysmography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101671 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000002 heart rate 380 beats/min 8.0 24.0 MMO:0000031 tail cuff plethysmography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101673 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000002 heart rate 339 beats/min 11.0 31.1127 MMO:0000031 tail cuff plethysmography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101675 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0001198 heart weight to tibia length ratio 0.263 g/cm 0.006 0.018 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101681 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000239 heart left ventricle posterior wall thickness 1.5 mm 0.02 0.06 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101711 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000239 heart left ventricle posterior wall thickness 2.06 mm 0.04 0.1131 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101713 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000982 heart left ventricle end-diastolic diameter 7.21 mm 0.21 0.63 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101715 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000982 heart left ventricle end-diastolic diameter 7.2 mm 0.14 0.396 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101717 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000985 heart left ventricle fractional shortening 39.8 % 2.5 7.5 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101719 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000985 heart left ventricle fractional shortening 47.7 % 1.9 5.374 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101721 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0001123 calculated heart left ventricle weight 764 mg 27.0 81.0 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101723 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0001123 calculated heart left ventricle weight 1114 mg 35.0 98.9949 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101725 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000988 heart left ventricle relative wall thickness 44 % 2.0 6.0 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101727 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000988 heart left ventricle relative wall thickness 57 % 2.0 5.6569 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101729 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002504 E wave deceleration time 35.4 ms 1.2 3.6 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101731 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002504 E wave deceleration time 56.9 ms 1.8 5.0912 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101733 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0001482 heart isovolumetric relaxation time 24.8 ms 1.8 5.4 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101735 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0001482 heart isovolumetric relaxation time 43.1 ms 1.5 4.2426 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101737 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002556 myocardial performance index 0.44 0.01 0.03 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101739 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002556 myocardial performance index 0.61 0.03 0.0849 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101741 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0000606 left ventricular end-diastolic blood pressure 2.27 mmHg 0.11 0.33 MMO:0000014 vascular transducer tipped catheter 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101743 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0000606 left ventricular end-diastolic blood pressure 4.43 mmHg 0.21 0.594 MMO:0000014 vascular transducer tipped catheter 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101745 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0001747 time constant of left ventricular pressure decay 36.2 ms 0.5 1.5 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101747 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0001747 time constant of left ventricular pressure decay 47.3 ms 1.5 4.2426 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101749 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004552 SS.ZUC-Leprfa+/+/Slc female 91 days 9 CMO:0002993 heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio 0.32 mmHg/mm 0.02 0.06 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101751 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0002993 heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio 0.63 mmHg/mm 0.05 0.1414 MMO:0000337 echocardiography 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101753 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000238 heart posterior wall thickness 0.206 cm 0.006 0.0216 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 101998 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000988 heart left ventricle relative wall thickness 49 % 1.0 3.6056 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102004 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000985 heart left ventricle fractional shortening 47.66 % 2.43 8.7615 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102007 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000180 ejection fraction 82.5 % 1.94 6.9948 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102010 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0002504 E wave deceleration time 53.05 ms 1.48 5.3362 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102013 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0001482 heart isovolumetric relaxation time 40.75 ms 2.42 8.7254 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102016 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0001747 time constant of left ventricular pressure decay 33.52 ms 1.09 3.9301 MMO:0000337 echocardiography 0.0 vehicle control condition (0.5 %) (for 28 days) 102019 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0000606 left ventricular end-diastolic blood pressure 17.65 mmHg 1.43 5.1559 MMO:0000014 vascular transducer tipped catheter 0.0 vehicle control condition (0.5 %) (for 28 days) 102022 vehicle control condition (0.5 %) (for 28 days) 2644 Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait RS:0004550 SS.ZUC-Leprfa-/-/Slc male 91 days 13 CMO:0002993 heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio 2.1 mmHg/mm 0.13 0.4687 MMO:0000014 vascular transducer tipped catheter 0.0 vehicle control condition (0.5 %) (for 28 days) 102025 vehicle control condition (0.5 %) (for 28 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. heart left ventricle end-diastolic diameter RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000982 heart left ventricle end-diastolic diameter 8.7 mm 0.3 0.8485 MMO:0000002 transthoracic echocardiography 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102320 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. kidney mass RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000340 both kidneys wet weight to body weight ratio 5.19 g/kg 0.19 0.5374 MMO:0000005 post excision weight measurement 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102323 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. blood creatinine amount RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000057 serum creatinine level 0.47 mg/dl 0.04 0.1131 MMO:0000271 serum creatinine analysis 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102326 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. blood urea nitrogen amount RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000587 serum urea nitrogen level 33.6 mg/dl 4.1 11.5966 MMO:0000274 serum urea nitrogen analysis 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102329 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. glomerular filtration trait RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000765 creatinine clearance 1.9 ml/min 0.5 1.4142 MMO:0000271 serum creatinine analysis 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102332 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. urine output RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000260 timed urine volume 53.6 ml/d 7.1 20.0818 MMO:0000357 urine volume measurement method 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102335 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2684 Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. total urine protein amount RS:0003328 SS/NEisSlc male 126 days 8 CMO:0000756 urine total protein excretion rate 307 mg/d 46.0 130.1076 MMO:0000334 urine protein analysis 0.0 controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) 102338 controlled sodium content diet (0.3 %) (for 42 days) controlled sodium content diet (8 %) (for 77 days) vehicle control condition (for 49 days) 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. arterial blood pressure trait RS:0001366 LL/Mav male 56 days 9 CMO:0000004 systolic blood pressure mean of 3 samples of undefined duration serial mean 115 mmHg 5.0 15.0 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102702 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. arterial blood pressure trait RS:0000556 LH/Mav male 56 days 11 CMO:0000004 systolic blood pressure mean of 3 samples of undefined duration serial mean 134 mmHg 4.0 13.2665 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102704 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine output RS:0001366 LL/Mav male 56 days 9 CMO:0000260 timed urine volume 9.1 ml/d 0.4 1.2 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102706 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine output RS:0000556 LH/Mav male 56 days 11 CMO:0000260 timed urine volume 8.7 ml/d 0.3 0.995 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102708 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. total urine protein amount RS:0001366 LL/Mav male 56 days 9 CMO:0000756 urine total protein excretion rate 26 mg/d 1.0 3.0 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102710 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. total urine protein amount RS:0000556 LH/Mav male 56 days 11 CMO:0000756 urine total protein excretion rate 70 mg/d 9.0 29.8496 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102712 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood glucose amount RS:0001366 LL/Mav male 56 days 9 CMO:0000046 blood glucose level 70 mg/dl 1.0 3.0 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) 102714 vehicle control condition fasting (for 16 hours) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. body mass RS:0004500 SD-Nfe2l2em1Mcwi+/+ male 11 days to 9 days 8 CMO:0000012 body weight 281 g 17.7 50.0632 MMO:0000016 body weighing method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) 100733 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) 2520 Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. body mass RS:0004501 SD-Nfe2l2em1Mcwi-/- male 11 days to 9 days 4 CMO:0000012 body weight 299 g 22.2 44.4 MMO:0000016 body weighing method 0.0 controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) 100734 controlled sodium content diet (0.4 %) (between 70 and 84 days) controlled sodium content diet (4 %) (for 6 days) vehicle control condition (for 3 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004555 SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc male 126 days 7 CMO:0000340 both kidneys wet weight to body weight ratio 3.77 g/kg 0.15 0.3969 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102161 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2761 Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5. arterial blood pressure trait RS:0000556 LH/Mav male 63 days 8 CMO:0000004 systolic blood pressure undefined 160 mmHg 3.0 8.4853 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102848 vehicle control condition 2761 Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5. arterial blood pressure trait RS:0000556 LH/Mav male 84 days 8 CMO:0000004 systolic blood pressure undefined 160 mmHg MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102849 vehicle control condition 2761 Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5. renal blood flow trait RS:0000556 LH/Mav male 84 days 8 CMO:0001955 renal blood flow rate to kidney weight ratio 5 ml/min/g 0.3 0.8485 MMO:0000228 ultrasonic flowmeter 0.0 vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) 102853 vehicle control condition ketamine (20 mg/kg) thiobutabarbital (75 mg/kg) 2761 Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5. kidney blood vessel physiology trait RS:0000556 LH/Mav male 84 days 8 CMO:0003218 renal vascular resistance to kidney weight ratio SBP/RBF 33 ml/min/g/mmHg 2.0 5.6569 MMO:0000228 ultrasonic flowmeter 0.0 vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) 102857 vehicle control condition ketamine (20 mg/kg) thiobutabarbital (75 mg/kg) 2622 Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass RS:0004550 SS.ZUC-Leprfa-/-/Slc female 91 days 8 CMO:0001198 heart weight to tibia length ratio 0.35 g/cm 0.0012 0.0034 MMO:0000005 post excision weight measurement 0.0 ovariectomy 42 days bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) 101693 bilateral ovariectomy (for 42 days) vehicle control condition (for 35 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004557 SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 4.25 g/kg 0.7 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102124 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. kidney mass RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 4.2 g/kg 0.62 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102125 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. drinking behavior trait RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0000741 water drink intake rate 78.62 ml/d 21.79 89.8425 MMO:0000697 metabolic cage water drinking measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102126 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. drinking behavior trait RS:0000761 WKY/Gcrc male 126 days 18 CMO:0000741 water drink intake rate 53.12 ml/d 30.74 130.4188 MMO:0000697 metabolic cage water drinking measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102127 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. drinking behavior trait RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0000741 water drink intake rate 58.47 ml/d 9.43 28.29 MMO:0000697 metabolic cage water drinking measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102128 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. drinking behavior trait RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0000741 water drink intake rate 57.55 ml/d 15.23 40.2948 MMO:0000697 metabolic cage water drinking measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102129 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. drinking behavior trait RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0000741 water drink intake rate 79.16 ml/d 16.78 41.1024 MMO:0000697 metabolic cage water drinking measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102130 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine output RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0000260 timed urine volume 55.29 ml/d 15.78 65.0626 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102131 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine output RS:0000761 WKY/Gcrc male 126 days 18 CMO:0000260 timed urine volume 31.8 ml/d 14.34 60.8395 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102132 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine output RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0000260 timed urine volume 34.03 ml/d 7.02 21.06 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102133 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine output RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0000260 timed urine volume 30.68 ml/d 11.32 29.9499 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102134 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine output RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0000260 timed urine volume 55.86 ml/d 8.67 21.2371 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102135 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine sodium amount RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0000129 urine sodium level 211.14 mmol/l 46.41 191.3533 MMO:0000434 urine sodium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102136 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine sodium amount RS:0000761 WKY/Gcrc male 126 days 18 CMO:0000129 urine sodium level 220.23 mmol/l 71.19 302.0336 MMO:0000434 urine sodium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102137 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle wall thickness RS:0000742 WKY male 252 days to 238 days 30 CMO:0000987 heart ventricle septal wall thickness 0.1 cm 0.004 0.0219 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100338 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter RS:0000742 WKY male 252 days to 238 days 30 CMO:0000982 heart left ventricle end-diastolic diameter 10.6 mm 0.1 0.5477 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100341 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter RS:0000742 WKY male 252 days to 238 days 30 CMO:0000983 heart left ventricle end-systolic diameter 8.9 mm 0.2 1.0954 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100344 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle posterior wall thickness RS:0000742 WKY male 252 days to 238 days 30 CMO:0000238 heart posterior wall thickness 0.18 cm 0.004 0.0219 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100347 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter RS:0000742 WKY male 252 days to 238 days 30 CMO:0000985 heart left ventricle fractional shortening 15.8 % 0.7 3.8341 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100350 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait RS:0000742 WKY male 252 days to 238 days 30 CMO:0000180 ejection fraction 37 % 1.4 7.6681 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100353 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood flow trait RS:0000742 WKY male 252 days to 238 days 30 CMO:0002789 E/A wave ratio 1.85 0.14 0.7668 MMO:0000337 echocardiography 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100356 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass RS:0000742 WKY male 252 days to 238 days 15 CMO:0000082 right kidney wet weight 1.3533 g 0.0439 0.17 MMO:0000005 post excision weight measurement 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100359 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output RS:0000742 WKY male 252 days to 238 days 7 CMO:0000260 timed urine volume 10.6 ml/d 2.2 5.8207 MMO:0000357 urine volume measurement method 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100362 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount RS:0000742 WKY male 252 days to 238 days 6 CMO:0000537 plasma creatinine level 0.52 mg/dl 0.04 0.098 MMO:0000306 plasma creatinine analysis 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100365 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine sodium amount RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0000129 urine sodium level 268.97 mmol/l 32.7 98.1 MMO:0000434 urine sodium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102138 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine sodium amount RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0000129 urine sodium level 260.49 mmol/l 36.69 97.0726 MMO:0000434 urine sodium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102139 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine sodium amount RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0000129 urine sodium level 169.89 mmol/l 27.46 67.263 MMO:0000434 urine sodium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102140 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine potassium amount RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0000128 urine potassium level 44.48 mmol/l 17.37 71.6183 MMO:0000435 urine potassium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102141 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine potassium amount RS:0000761 WKY/Gcrc male 126 days 18 CMO:0000128 urine potassium level 71.25 mmol/l 33.04 140.1768 MMO:0000435 urine potassium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102142 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine potassium amount RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0000128 urine potassium level 72.41 mmol/l 20.37 61.11 MMO:0000435 urine potassium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102143 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine potassium amount RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0000128 urine potassium level 80.72 mmol/l 27.0 71.4353 MMO:0000435 urine potassium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102144 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine potassium amount RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0000128 urine potassium level 28.25 mmol/l 8.59 21.0411 MMO:0000435 urine potassium analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102145 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0002924 urine urea level 131.16 mmol/l 57.62 237.5733 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102146 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0000761 WKY/Gcrc male 126 days 18 CMO:0002924 urine urea level 235.52 mmol/l 90.62 384.4681 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102147 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0002924 urine urea level 228.93 mmol/l 62.26 186.78 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102148 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0002924 urine urea level 316.61 mmol/l 113.57 300.478 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102149 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine urea amount RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0002924 urine urea level 103 mmol/l 34.23 83.846 MMO:0000676 urine urea analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102150 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine creatinine amount RS:0000760 SHRSP/Gcrc male 126 days 17 CMO:0000125 urine creatinine level 6.85368 mg/dl 2.7655 11.4025 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102151 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine creatinine amount RS:0000761 WKY/Gcrc male 126 days 18 CMO:0000125 urine creatinine level 13.90776 mg/dl 5.2906 22.4459 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102152 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine creatinine amount RS:0003568 SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc male 126 days 9 CMO:0000125 urine creatinine level 10.4208 mg/dl 1.8036 5.4108 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102153 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine creatinine amount RS:0004556 SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc male 126 days 7 CMO:0000125 urine creatinine level 12.38472 mg/dl 3.6072 9.5438 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102154 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2646 Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155. urine creatinine amount RS:0004558 SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc male 126 days 6 CMO:0000125 urine creatinine level 5.37072 mg/dl 1.523 3.7307 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) 102155 vehicle control condition (for 126 days) sodium chloride solution (1 %) (for 21 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. body mass RS:0000731 WKY/NCrl male 168 days 6 CMO:0000012 body weight 463 g 7.0 17.1464 MMO:0000016 body weighing method 0.0 vehicle control condition (for 28 days) 103490 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. body mass RS:0001299 GK male 168 days 6 CMO:0000012 body weight 380 g 7.0 17.1464 MMO:0000016 body weighing method 0.0 vehicle control condition (for 28 days) 103492 vehicle control condition (for 28 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. drinking behavior trait RS:0000731 WKY/NCrl male 175 days to 140 days 6 CMO:0002859 water intake drink rate to body weight ratio 50 ml/d/kg 1.0 2.4495 MMO:0000619 drink intake measuring method vehicle control condition (between 1 and 35 days) 103498 vehicle control condition (between 1 and 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. drinking behavior trait RS:0001299 GK male 175 days to 140 days 6 CMO:0002859 water intake drink rate to body weight ratio 99 ml/d/kg 13.0 31.8434 MMO:0000619 drink intake measuring method vehicle control condition (between 1 and 35 days) 103500 vehicle control condition (between 1 and 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood fructosamine amount RS:0000731 WKY/NCrl male 175 days 6 CMO:0002856 serum fructosamine level 153 umol/l 3.0 7.3485 MMO:0000708 serum fructosamine analysis 0.0 vehicle control condition (for 35 days) 103502 vehicle control condition (for 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood fructosamine amount RS:0001299 GK male 175 days 6 CMO:0002856 serum fructosamine level 187 umol/l 9.0 22.0454 MMO:0000708 serum fructosamine analysis 0.0 vehicle control condition (for 35 days) 103504 vehicle control condition (for 35 days) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount RS:0000731 WKY/NCrl male 168 days 6 CMO:0000046 blood glucose level 113 mg/dl 4.0 9.798 MMO:0000165 blood glucose test strip read by electrochemical glucometer 0.0 vehicle control condition (for 28 days) then fasting (for 16 hours) 103510 vehicle control condition (for 28 days) fasting (for 16 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount RS:0001299 GK male 168 days 6 CMO:0000046 blood glucose level 122 mg/dl 8.0 19.5959 MMO:0000165 blood glucose test strip read by electrochemical glucometer 0.0 vehicle control condition (for 28 days) then fasting (for 16 hours) 103512 vehicle control condition (for 28 days) fasting (for 16 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount RS:0000731 WKY/NCrl male 168 days 6 CMO:0000046 blood glucose level 125 mg/dl 3.0 7.3485 MMO:0000113 oral glucose tolerance test 0.0 vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) 103518 vehicle control condition (for 28 days) fasting (for 16 hours) glucose (2 g/kg) (for 2 hours) 2827 Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount RS:0001299 GK male 168 days 6 CMO:0000046 blood glucose level 278 mg/dl 20.0 48.9898 MMO:0000113 oral glucose tolerance test 0.0 vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) 103520 vehicle control condition (for 28 days) fasting (for 16 hours) glucose (2 g/kg) (for 2 hours) 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. body mass RS:0001366 LL/Mav male 56 days 9 CMO:0000012 body weight 231 g 4.0 12.0 MMO:0000016 body weighing method 0.0 vehicle control condition 102698 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. body mass RS:0000556 LH/Mav male 56 days 11 CMO:0000012 body weight 246 g 4.0 13.2665 MMO:0000016 body weighing method 0.0 vehicle control condition 102700 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood glucose amount RS:0001366 LL/Mav male 56 days 9 CMO:0000046 blood glucose level 136 mg/dl 4.0 12.0 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) 102718 vehicle control condition fasting (for 16 hours) glucose (2 g/kg) (for 1 hours) 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. body mass RS:0001366 LL/Mav male 112 days 9 CMO:0000012 body weight 364 g 6.0 18.0 MMO:0000016 body weighing method 0.0 vehicle control condition 102722 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. body mass RS:0000556 LH/Mav male 112 days 11 CMO:0000012 body weight 384 g 9.0 29.8496 MMO:0000016 body weighing method 0.0 vehicle control condition 102724 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood glucose amount RS:0000556 LH/Mav male 56 days 11 CMO:0000046 blood glucose level 69 mg/dl 1.0 3.3166 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) 102716 vehicle control condition fasting (for 16 hours) 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood glucose amount RS:0000556 LH/Mav male 56 days 11 CMO:0000046 blood glucose level 127 mg/dl 3.0 9.9499 MMO:0000112 blood glucose analysis 0.0 vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) 102720 vehicle control condition fasting (for 16 hours) glucose (2 g/kg) (for 1 hours) 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. arterial blood pressure trait RS:0001366 LL/Mav male 112 days 9 CMO:0000004 systolic blood pressure mean of 3 samples of undefined duration serial mean 119 mmHg 4.0 12.0 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102726 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. arterial blood pressure trait RS:0000556 LH/Mav male 112 days 11 CMO:0000004 systolic blood pressure mean of 3 samples of undefined duration serial mean 160 mmHg 4.0 13.2665 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition 102728 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine output RS:0001366 LL/Mav male 112 days 9 CMO:0000260 timed urine volume 12.4 ml/d 0.6 1.8 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102730 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine output RS:0000556 LH/Mav male 112 days 11 CMO:0000260 timed urine volume 11.6 ml/d 0.4 1.3266 MMO:0000357 urine volume measurement method 0.0 vehicle control condition 102732 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. total urine protein amount RS:0001366 LL/Mav male 112 days 9 CMO:0000756 urine total protein excretion rate 37 mg/d 1.0 3.0 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102734 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. total urine protein amount RS:0000556 LH/Mav male 112 days 11 CMO:0000756 urine total protein excretion rate 135 mg/d 21.0 69.6491 MMO:0000334 urine protein analysis 0.0 vehicle control condition 102736 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine albumin amount RS:0001366 LL/Mav male 112 days 9 CMO:0000757 urine albumin excretion rate 4.4 mg/d 0.3 0.9 MMO:0000406 urine albumin analysis 0.0 vehicle control condition 102738 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine albumin amount RS:0000556 LH/Mav male 112 days 11 CMO:0000757 urine albumin excretion rate 24 mg/d 4.6 15.2565 MMO:0000406 urine albumin analysis 0.0 vehicle control condition 102740 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine creatinine amount RS:0001366 LL/Mav male 112 days 9 CMO:0000764 urine creatinine excretion rate 11.1 mg/d 0.5 1.5 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition 102746 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. urine creatinine amount RS:0000556 LH/Mav male 112 days 11 CMO:0000764 urine creatinine excretion rate 12.9 mg/d 0.4 1.3266 MMO:0000275 urine creatinine analysis 0.0 vehicle control condition 102748 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood cholesterol amount RS:0001366 LL/Mav male 112 days 9 CMO:0000585 plasma total cholesterol level 62.5482 mg/dl 4.2471 12.7413 MMO:0000284 plasma total cholesterol measurement test 0.0 vehicle control condition 102750 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood cholesterol amount RS:0000556 LH/Mav male 112 days 11 CMO:0000585 plasma total cholesterol level 90.3474 mg/dl 7.3359 24.3304 MMO:0000284 plasma total cholesterol measurement test 0.0 vehicle control condition 102752 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood triglyceride amount RS:0001366 LL/Mav male 112 days 9 CMO:0000548 plasma triglyceride level 1.4 mmol/l 0.11 0.33 MMO:0000234 plasma triglyceride analysis 0.0 vehicle control condition 102754 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood triglyceride amount RS:0000556 LH/Mav male 112 days 11 CMO:0000548 plasma triglyceride level 1.43 mmol/l 0.16 0.5307 MMO:0000234 plasma triglyceride analysis 0.0 vehicle control condition 102756 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood creatinine amount RS:0001366 LL/Mav male 112 days 9 CMO:0000537 plasma creatinine level 0.501 mg/dl 0.01 0.03 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102758 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. blood creatinine amount RS:0000556 LH/Mav male 112 days 11 CMO:0000537 plasma creatinine level 0.519 mg/dl 0.009 0.0298 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102760 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. kidney mass RS:0001366 LL/Mav male 112 days 9 CMO:0000340 both kidneys wet weight to body weight ratio 6.08 g/kg 0.07 0.21 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102762 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. kidney mass RS:0000556 LH/Mav male 112 days 11 CMO:0000340 both kidneys wet weight to body weight ratio 6.24 g/kg 0.07 0.2322 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102764 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. heart left ventricle mass RS:0001366 LL/Mav male 112 days 9 CMO:0000530 heart left ventricle weight to body weight ratio 1.88 mg/g 0.002 0.006 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102766 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. heart left ventricle mass RS:0000556 LH/Mav male 112 days 11 CMO:0000530 heart left ventricle weight to body weight ratio 2.24 mg/g 0.003 0.0099 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102768 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. aorta mass RS:0001366 LL/Mav male 112 days 9 CMO:0003216 aorta weight to body weight ratio 11.2 mg/100g 0.2 0.6 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102770 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. aorta mass RS:0000556 LH/Mav male 112 days 11 CMO:0003216 aorta weight to body weight ratio 13.5 mg/100g 0.2 0.6633 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 102772 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. glomerular filtration trait RS:0001366 LL/Mav male 112 days 9 CMO:0000765 creatinine clearance 1.53 ml/min 0.07 0.21 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102774 vehicle control condition 2721 Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. glomerular filtration trait RS:0000556 LH/Mav male 112 days 11 CMO:0000765 creatinine clearance 1.6 ml/min 0.1 0.3317 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition 102776 vehicle control condition 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle integrity trait RS:0000742 WKY male 252 days to 238 days 30 CMO:0000687 heart left ventricle infarction size to total heart left ventricle size ratio 35.8 % 5.4 29.577 MMO:0000219 ex vivo microscopy with digital image analysis 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100264 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass RS:0000742 WKY male 56 days to 42 days 30 CMO:0000012 body weight 225 g 1.8 9.859 MMO:0000016 body weighing method 0.0 lad occlusion 0 days left anterior descending coronary artery occlusion then vehicle control condition 100269 left anterior descending coronary artery occlusion vehicle control condition 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass RS:0000742 WKY male 252 days to 238 days 30 CMO:0000012 body weight 617 g 52.0 284.8157 MMO:0000016 body weighing method 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100272 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass RS:0000742 WKY male 252 days to 238 days 30 CMO:0000017 heart weight 1.573 g 0.28 1.5336 MMO:0000005 post excision weight measurement 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100278 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass RS:0000742 WKY male 252 days to 238 days 30 CMO:0000776 heart left ventricle weight 0.969 g 0.079 0.4327 MMO:0000005 post excision weight measurement 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100290 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2460 Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. lung mass RS:0000742 WKY male 252 days to 238 days 30 CMO:0000097 lung wet weight 2.134 g 0.13 0.712 MMO:0000005 post excision weight measurement 0.0 lad occlusion 196 days left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) 100299 left anterior descending coronary artery occlusion (for 196 days) vehicle control condition (for 182 days) 2499 Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. body mass RS:0000681 SD female 0 days 13 CMO:0000012 body weight 283.6 g 3.8 13.7011 MMO:0000016 body weighing method 0.0 unx 97 days controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) 100632 controlled calcium content diet (0.6 %) (for 97 days) controlled content diet (0.9 %) (for 97 days) unilateral nephrectomy (for 97 days) vehicle control condition (100 ul) (for 90 days) 2499 Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. blood creatinine amount RS:0000681 SD female 0 days 13 CMO:0000057 serum creatinine level 1.65 mg/dl 0.14 0.5048 MMO:0000271 serum creatinine analysis 0.0 unx 97 days controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) 100637 controlled calcium content diet (0.6 %) (for 97 days) controlled content diet (0.9 %) (for 97 days) unilateral nephrectomy (for 97 days) vehicle control condition (100 ul) (for 90 days) 2499 Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. glomerular filtration trait RS:0000681 SD female 0 days 13 CMO:0000765 creatinine clearance 0.3 ml/min 0.03 0.1082 MMO:0000271 serum creatinine analysis 0.0 unx 97 days controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) 100642 controlled calcium content diet (0.6 %) (for 97 days) controlled content diet (0.9 %) (for 97 days) unilateral nephrectomy (for 97 days) vehicle control condition (100 ul) (for 90 days) 2499 Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. blood parathyroid hormone amount RS:0000681 SD female 0 days 13 CMO:0002963 serum parathyroid hormone level 3496 pg/ml 862.0 3107.9852 MMO:0000690 serum parathyroid hormone analysis 0.0 unx 97 days controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) 100647 controlled calcium content diet (0.6 %) (for 97 days) controlled content diet (0.9 %) (for 97 days) unilateral nephrectomy (for 97 days) vehicle control condition (100 ul) (for 90 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. blood urea nitrogen amount RS:0001381 PCK-Pkhd1pck/CrljCrl male 112 days 5 CMO:0000049 blood urea nitrogen level 20.6 mg/dl 1.8 4.0249 MMO:0000253 blood urea nitrogen analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100763 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. blood urea nitrogen amount RS:0000064 Crl:CD(SD) male 112 days 5 CMO:0000049 blood urea nitrogen level 19.3 mg/dl 2.6 5.8138 MMO:0000253 blood urea nitrogen analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100764 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. blood creatinine amount RS:0001381 PCK-Pkhd1pck/CrljCrl male 112 days 5 CMO:0000057 serum creatinine level 0.51 mg/dl 0.04 0.0894 MMO:0000271 serum creatinine analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100765 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. blood creatinine amount RS:0000064 Crl:CD(SD) male 112 days 5 CMO:0000057 serum creatinine level 0.43 mg/dl 0.03 0.0671 MMO:0000271 serum creatinine analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100766 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. total urine protein amount RS:0000064 Crl:CD(SD) male 112 days 5 CMO:0000756 urine total protein excretion rate 36.7 mg/d 3.5 7.8262 MMO:0000334 urine protein analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100768 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. total urine protein amount RS:0001381 PCK-Pkhd1pck/CrljCrl male 112 days 6 CMO:0002758 urine protein level to urine creatinine level ratio 12 1.7 4.1641 MMO:0000334 urine protein analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100769 control condition (for 28 days) vehicle control condition (for 84 days) 2521 Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13. total urine protein amount RS:0000064 Crl:CD(SD) male 112 days 5 CMO:0002758 urine protein level to urine creatinine level ratio 1.98 0.31 0.6932 MMO:0000334 urine protein analysis 0.0 control condition (for 28 days) then vehicle control condition (for 84 days) 100770 control condition (for 28 days) vehicle control condition (for 84 days) 2784 Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. arterial blood pressure trait RS:0001299 GK male 16 days 5 CMO:0000009 mean arterial blood pressure undefined 118 mmHg 7.0 15.6525 MMO:0000014 vascular transducer tipped catheter 0.0 air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 103025 air oxygen content (21 %) (for 28 days) vehicle control condition (0.15 ml) (for 0.1 hours) acetylcholine (5 ug/kg/min) (for 0.1 hours) sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart pumping trait RS:0000811 SS/JrHsdMcwi male 56 days 6 CMO:0000002 heart rate 358 beats/min 7.95 19.4734 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106798 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart pumping trait RS:0001480 SS-Sod3m1Mcwi male 56 days 8 CMO:0000002 heart rate 354 beats/min 12.9 36.4867 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106799 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0000811 SS/JrHsdMcwi male 56 days 6 CMO:0000004 systolic blood pressure 115 mmHg 4.76 11.6596 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106802 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0001480 SS-Sod3m1Mcwi male 56 days 8 CMO:0000004 systolic blood pressure 115 mmHg 5.22 14.7644 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106803 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0000811 SS/JrHsdMcwi male 56 days 6 CMO:0000005 diastolic blood pressure 84 mmHg 4.05 9.9204 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106806 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0001480 SS-Sod3m1Mcwi male 56 days 8 CMO:0000005 diastolic blood pressure 84.2 mmHg 4.96 14.029 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106807 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0000811 SS/JrHsdMcwi male 56 days 6 CMO:0003285 mean aortic pressure Mean aortic pressure 94.4 mmHg 4.27 10.4593 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106810 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. arterial blood pressure trait RS:0001480 SS-Sod3m1Mcwi male 56 days 8 CMO:0003285 mean aortic pressure Mean aortic pressure 94.5 mmHg 5.02 14.1987 MMO:0000013 vascular fluid filled catheter 0.0 vehicle control condition 106811 vehicle control condition 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood creatinine amount RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0000537 plasma creatinine level 0.59049684 mg/dl 0.0498 0.1574 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition (for 547.5 days) 107421 vehicle control condition (for 547.5 days) 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. total urine protein amount RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0000756 urine total protein excretion rate 215.9 mg/d 15.3 48.3828 MMO:0000335 urine total protein analysis 0.0 vehicle control condition (for 547.5 days) 107437 vehicle control condition (for 547.5 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span RS:0000775 SHRSP/A3N male 168 days to 147 days 25 CMO:0003800 ratio of deaths related to chronic hypertension to total study population during a period of time ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 95 % MMO:0000160 unspecified method 0.0 controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days) 107518 controlled sodium chloride content drinking water (1 %) (for 63 days) controlled fat content diet (24.5 %) (for 63 days) vehicle control condition (for 63 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total urine protein amount RS:0000775 SHRSP/A3N male 154 days to 119 days N/A CMO:0000756 urine total protein excretion rate 127 mg/d 13.0 MMO:0000334 urine protein analysis 86400.0 controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and vehicle control condition (between 35 and 49 days) 107520 controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) controlled fat content diet (24.5 %) (between 35 and 49 days) vehicle control condition (between 35 and 49 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. body mass RS:0000775 SHRSP/A3N male 147 days to 126 days N/A CMO:0000012 body weight 254 g 7.0 MMO:0000016 body weighing method 0.0 controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days) 107527 controlled sodium chloride content drinking water (1 %) (for 42 days) controlled fat content diet (24.5 %) (for 42 days) vehicle control condition (for 42 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0000081 kidney weight 2.65 g 0.1 MMO:0000005 post excision weight measurement kidney 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107531 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. body mass RS:0001011 Crl:WI male 112 days 10 CMO:0000012 body weight 391.8 g 17.2 54.3912 MMO:0000016 body weighing method 0.0 vehicle control condition (for 28 days) 109387 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. body mass RS:0000596 MWF/FubRkb male 112 days 10 CMO:0000012 body weight 362.8 g 12.8 40.4772 MMO:0000016 body weighing method 0.0 vehicle control condition (for 28 days) 109389 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. tibia length RS:0001011 Crl:WI male 113 days 10 CMO:0000450 tibia length 4 cm 1.0 3.1623 MMO:0000276 post excision length measurement 0.0 vehicle control condition (for 28 days) 109395 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. tibia length RS:0000596 MWF/FubRkb male 113 days 10 CMO:0000450 tibia length 4.2 cm 1.0 3.1623 MMO:0000276 post excision length measurement 0.0 vehicle control condition (for 28 days) 109397 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. urine output RS:0001011 Crl:WI male 114 days 10 CMO:0000260 timed urine volume 11.1 ml/d 1.3 4.111 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 28 days) 109399 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. urine output RS:0000596 MWF/FubRkb male 114 days 10 CMO:0000260 timed urine volume 10.1 ml/d 0.4 1.2649 MMO:0000511 metabolic cage urine volume measurement method 0.0 vehicle control condition (for 28 days) 109401 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. urine albumin amount RS:0001011 Crl:WI male 114 days 10 CMO:0000757 urine albumin excretion rate 0.17 mg/d 0.01 0.0316 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition (for 28 days) 109403 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. urine albumin amount RS:0000596 MWF/FubRkb male 114 days 10 CMO:0000757 urine albumin excretion rate 64.4 mg/d 5.6 17.7088 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition (for 28 days) 109405 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. arterial blood pressure trait RS:0001011 Crl:WI male 112 days 10 CMO:0000004 systolic blood pressure 126.9 mmHg 4.0 12.6491 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition (10 mg/kg/d) (for 28 days) 109407 vehicle control condition (10 mg/kg/d) (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. arterial blood pressure trait RS:0000596 MWF/FubRkb male 112 days 10 CMO:0000004 systolic blood pressure 151.5 mmHg 9.0 28.4605 MMO:0000031 tail cuff plethysmography 0.0 vehicle control condition (10 mg/kg/d) (for 28 days) 109409 vehicle control condition (10 mg/kg/d) (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. heart pumping trait RS:0001011 Crl:WI male 112 days 10 CMO:0000002 heart rate 355.3 beats/min 9.7 30.6741 MMO:0000031 tail cuff plethysmography heart 0.0 vehicle control condition (for 28 days) 109411 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. heart pumping trait RS:0000596 MWF/FubRkb male 112 days 10 CMO:0000002 heart rate 352.3 beats/min 7.3 23.0846 MMO:0000031 tail cuff plethysmography heart 0.0 vehicle control condition (for 28 days) 109413 vehicle control condition (for 28 days) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait RS:0000742 WKY male 0 days 17 CMO:0003489 kidney glomerular tuft surface area 13.2 x 10E3 um2 3.3 13.6062 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 unx 150 days unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition 107511 unilateral nephrectomy (for 150 days) streptozotocin (35 mg/kg) vehicle control condition 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0003443 kidney tubule regeneration foci count 27.3 /section 2.9 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107547 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0003445 interstitial nephritis foci count 8.5 /section 1.2 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107551 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood cholesterol amount RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0000585 plasma total cholesterol level 74.4 mg/dl 4.1 12.9653 MMO:0000284 plasma total cholesterol measurement test 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107781 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood cholesterol amount RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0000585 plasma total cholesterol level 59.5 mg/dl 3.2 10.1193 MMO:0000284 plasma total cholesterol measurement test 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107784 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood HDL phospholipid amount RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0001566 plasma high density lipoprotein phospholipid level 47.1 mg/dl 4.1 12.9653 MMO:0000282 plasma high-density lipoprotein-cholesterol measurement test 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107787 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood HDL phospholipid amount RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0001566 plasma high density lipoprotein phospholipid level 36.2 mg/dl 2.4 7.5895 MMO:0000282 plasma high-density lipoprotein-cholesterol measurement test 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107790 vehicle control condition (2 ml/kg) (for 1 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0001350 platelet distribution width 8.7 fl 0.1581 0.5 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107882 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0001350 platelet distribution width 8.6 fl 0.0316 0.1 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107884 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount serum BUN RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000587 serum urea nitrogen level 35 mg/dl 0.5692 1.8 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107887 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount serum BUN RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000587 serum urea nitrogen level 34.5 mg/dl 0.4111 1.3 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107889 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass RS:0000742 WKY male 0 days 17 CMO:0001954 left kidney wet weight to body weight ratio 9.9 mg/g 0.7 2.8862 MMO:0000005 post excision weight measurement 0.0 unx 150 days unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition 107456 unilateral nephrectomy (for 150 days) streptozotocin (35 mg/kg) vehicle control condition 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0001348 mean platelet volume 5.9 fl 0.0316 0.1 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107821 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0001348 mean platelet volume 5.9 fl 0.0632 0.2 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107823 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity WBC RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000365 total white blood cell count 12.9 x 1000 cells/ul 0.6325 2.0 MMO:0000144 automated total white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107826 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity WBC RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000365 total white blood cell count 10 x 1000 cells/ul 0.3479 1.1 MMO:0000144 automated total white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107828 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000026 blood hemoglobin level 19.9 g/dl 0.6641 2.1 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107831 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000026 blood hemoglobin level 18.9 g/dl 0.4743 1.5 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107833 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0003444 kidney total tubule cast count 349 /section 45.0 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107555 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0003446 renal fibrosis foci count 16.4 /section 1.4 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107559 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. arterial blood pressure trait RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0000004 systolic blood pressure 137 mmHg 3.0 9.4868 MMO:0000011 vascular indwelling catheter method femoral artery 0.0 vehicle control condition (for 547.5 days) 106791 vehicle control condition (for 547.5 days) 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. heart mass RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0000074 heart weight to body weight ratio 3.2 g/kg 0.1 0.3162 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (for 547.5 days) 106792 vehicle control condition (for 547.5 days) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass RS:0000742 WKY male 0 days 17 CMO:0000012 body weight 256 g 5.0 20.6155 MMO:0000016 body weighing method 0.0 unx 150 days unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition 107446 unilateral nephrectomy (for 150 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass RS:0000742 WKY male 0 days 17 CMO:0000074 heart weight to body weight ratio 3.5 g/kg 0.1 0.4123 MMO:0000005 post excision weight measurement 0.0 unx 150 days unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition 107451 unilateral nephrectomy (for 150 days) streptozotocin (35 mg/kg) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait RS:0000742 WKY male 0 days 17 CMO:0003488 kidney glomerular surface area kidney glomerulus surface area (CMO:0003488) 19.3 x 10E3 um2 4.8 19.7909 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 unx 150 days unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition 107461 unilateral nephrectomy (for 150 days) streptozotocin (35 mg/kg) vehicle control condition 3128 Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. cone electrophysiology trait RS:0000698 Hsd:SD both 0 days 4 CMO:0003702 photopic B wave amplitude of ERG waveform photopic b-wave ERG 51 uV MMO:0000616 electroretinography cornea 0.0 subretinal injection 30 days vehicle control condition (2 ul) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) 108644 vehicle control condition (2 ul) controlled visible light condition (30 cd x s/m2) visible light stimulus (12 cd/m2) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymus mass RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0000612 thymus weight to body weight ratio 0.77 mg/g 0.09 0.2846 MMO:0000005 post excision weight measurement 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107688 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymus mass RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0000612 thymus weight to body weight ratio 1.95 mg/g 0.77 2.435 MMO:0000005 post excision weight measurement 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107689 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0001843 thymocyte count 1028.62 x10E6/organ 146.62 463.6532 MMO:0000224 isolated cell counting method 0.0 IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107693 vehicle control condition (2 ml/kg) (for 1 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity red blood cell count, hematocrit RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000025 red blood cell count 11 x 10E6 cells/ul 0.4111 1.3 MMO:0000146 automated blood cell counting method 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107801 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait MCV, RDW% RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000038 mean corpuscular volume 47.5 fl 0.0316 0.1 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107806 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait MCV, RDW% RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000038 mean corpuscular volume 47.5 fl 0.1897 0.6 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107808 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity red blood cell count, hematocrit RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000037 hematocrit 52.3 % 0.9487 3.0 MMO:0000214 hematocrit analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107811 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity red blood cell count, hematocrit RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000037 hematocrit 51 % 1.0436 3.3 MMO:0000214 hematocrit analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107813 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3128 Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait RS:0000698 Hsd:SD both 0 days 4 CMO:0003706 scotopic A wave amplitude of ERG waveform scotopic a-wave ERG 142 uV MMO:0000616 electroretinography cornea 0.0 subretinal injection 30 days vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) 108642 vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours) visible light stimulus (5 cd/m2) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait RS:0000742 WKY male 0 days 11 CMO:0003489 kidney glomerular tuft surface area 8.7 x 10E3 um2 2.6 8.6232 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 unx 150 days unilateral nephrectomy (for 150 days) then vehicle control condition 107510 unilateral nephrectomy (for 150 days) vehicle control condition 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. spleen morphology trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0002117 spleen cell count 707.11 x10E6/organ 150.29 475.2587 MMO:0000224 isolated cell counting method 0.0 saline IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107700 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. spleen morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0002117 spleen cell count 583.56 x10E6/organ 109.7 346.9019 MMO:0000224 isolated cell counting method 0.0 saline IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107703 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. T cell development trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003521 apoptotic hypodiploid thymocyte count to total thymocyte count ratio 0.45 % 0.12 0.3795 MMO:0000617 flow cytometry method 0.0 saline IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107706 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. T cell development trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003523 G0 stage diploid thymocyte count to total thymocyte count ratio 93.31 % 0.93 2.9409 MMO:0000617 flow cytometry method 0.0 saline IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107709 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. T cell development trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003524 G2/M stage tetraploid thymocyte count to total thymocyte count ratio 2.62 % 0.29 0.9171 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107712 vehicle control condition (2 ml/kg) (for 1 days) 3098 Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. body mass RS:0000967 WAG male 0 days 16 CMO:0000012 body weight 272.4 g 3.35 13.4 MMO:0000016 body weighing method 0.0 cells and vehicle injected IP injection 21 days CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) 107872 CC531 cells (5 X 10E6) (for 21 days) vehicle control condition (1 ml) (for 21 days) 3098 Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. peritoneum integrity trait RS:0000968 WAG/OlaHsd male 0 days 16 CMO:0003554 metastatic intraperitoneal tumor weight abdominal lesion weight 7.42 g 0.2525 1.01 MMO:0000344 necropsy 0.0 CC531 cells IP injection 21 days CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) 107874 CC531 cells (5 X 10E6) (for 21 days) vehicle control condition (1 ml) (for 21 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount serum total cholesterol RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000363 serum total cholesterol level 40.5 mg/dl 1.7076 5.4 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107894 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount serum alanine aminotransferase RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000575 serum alanine aminotransferase activity level 59.2 U/l 1.9922 6.3 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107907 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount serum alanine aminotransferase RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000575 serum alanine aminotransferase activity level 44.8 U/l 2.9409 9.3 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107909 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount serum alkaline phosphatase RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000577 serum alkaline phosphatase activity level 476 U/l 1.5811 5.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107912 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount serum amylase RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0003519 serum amylase activity level 3096 U/l 32.2552 102.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107944 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3128 Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait RS:0000698 Hsd:SD both 0 days 4 CMO:0003705 scotopic B wave amplitude of ERG waveform scotopic b-wave ERG 338 uV MMO:0000616 electroretinography cornea 0.0 subretinal injection 30 days vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) 108640 vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours) visible light stimulus (5 cd/m2) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass RS:0000742 WKY male 0 days 11 CMO:0000012 body weight 408 g 10.0 33.1662 MMO:0000016 body weighing method 0.0 unx 150 days unilateral nephrectomy (for 150 days) then vehicle control condition 107445 unilateral nephrectomy (for 150 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass RS:0000742 WKY male 0 days 11 CMO:0000074 heart weight to body weight ratio 2.4 g/kg 0.1 0.3317 MMO:0000005 post excision weight measurement 0.0 unx 150 days unilateral nephrectomy (for 150 days) then vehicle control condition 107450 unilateral nephrectomy (for 150 days) vehicle control condition 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity red blood cell count, hematocrit RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000025 red blood cell count 10.7 x 10E6 cells/ul 0.253 0.8 MMO:0000146 automated blood cell counting method 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107803 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. thymus mass RS:0000698 Hsd:SD female 84 days 10 CMO:0000612 thymus weight to body weight ratio 1.5 mg/g 0.35 1.1068 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105884 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. thymus mass RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000612 thymus weight to body weight ratio 1.61 mg/g 0.19 0.6008 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105885 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. spleen mass RS:0000698 Hsd:SD female 84 days 10 CMO:0000149 spleen weight to body weight ratio 0.299 % 0.027 0.0854 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105896 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. spleen mass RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000149 spleen weight to body weight ratio 0.286 % 0.022 0.0696 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105897 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. brain mass RS:0000698 Hsd:SD female 84 days 10 CMO:0000139 brain weight to body weight ratio 0.742 % 0.031 0.098 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105908 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. brain mass RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000139 brain weight to body weight ratio 0.742 % 0.044 0.1391 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105909 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. ovary mass RS:0000698 Hsd:SD female 84 days 10 CMO:0003019 both ovaries weight to body weight ratio 0.049 % 0.011 0.0348 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105920 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. ovary mass RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0003019 both ovaries weight to body weight ratio 0.047 % 0.007 0.0221 MMO:0000005 post excision weight measurement vehicle control condition (5 ml/kg) (for 28 days) 105921 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000025 red blood cell count 7.47 x 10E6 cells/ul 0.21 0.6641 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105932 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000025 red blood cell count 7.41 x 10E6 cells/ul 0.36 1.1384 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105933 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0000698 Hsd:SD female 84 days 10 CMO:0000026 blood hemoglobin level 14.05 g/dl 0.48 1.5179 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105944 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000026 blood hemoglobin level 14.01 g/dl 0.62 1.9606 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105945 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000037 hematocrit 43.31 % 1.49 4.7118 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105956 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000037 hematocrit 43.31 % 1.67 5.281 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105957 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte size trait RS:0000698 Hsd:SD female 84 days 10 CMO:0000038 mean corpuscular volume 57.96 fl 1.26 3.9845 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105968 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. erythrocyte size trait RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000038 mean corpuscular volume 58.44 fl 0.87 2.7512 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105969 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0000698 Hsd:SD female 84 days 10 CMO:0000290 mean corpuscular hemoglobin 18.82 pg 0.44 1.3914 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105980 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000290 mean corpuscular hemoglobin 18.92 pg 0.39 1.2333 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105981 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0000698 Hsd:SD female 84 days 10 CMO:0000291 mean corpuscular hemoglobin concentration 32.48 g/dl 0.68 2.1503 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105992 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. blood hemoglobin amount RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000291 mean corpuscular hemoglobin concentration 32.37 g/dl 0.7 2.2136 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 105993 vehicle control condition (5 ml/kg) (for 28 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0003526 platelet distribution width (percentage) 5.2 % 0.0 0.0 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 108146 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0003526 platelet distribution width (percentage) 8.5 % 0.0 0.0 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 108148 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasodilation trait RS:0001011 Crl:WI male 114 days 10 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 90.3 % 1.2 3.7947 MMO:0000342 wire myography mesenteric artery 0.0 vehicle control condition (for 28 days) 109431 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasodilation trait RS:0000596 MWF/FubRkb male 114 days 10 CMO:0000731 acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel 82.3 % 3.0 9.4868 MMO:0000342 wire myography mesenteric artery 0.0 vehicle control condition (for 28 days) 109433 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasoconstriction trait RS:0001011 Crl:WI male 114 days 10 CMO:0003726 norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL 51.3 % 4.7 14.8627 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 109439 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasoconstriction trait RS:0000596 MWF/FubRkb male 114 days 10 CMO:0003726 norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL 77.8 % 10.2 32.2552 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 109441 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasoconstriction trait RS:0001011 Crl:WI male 114 days 10 CMO:0003727 negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value 6.7 0.1 0.3162 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 109443 vehicle control condition (for 28 days) 3140 Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. vasoconstriction trait RS:0000596 MWF/FubRkb male 114 days 10 CMO:0003727 negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value 6.9 0.1 0.3162 MMO:0000342 wire myography 0.0 vehicle control condition (for 28 days) 109445 vehicle control condition (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. platelet quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000029 platelet count 1308.4 x 1000 cells/ul 220.08 695.9541 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106004 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. platelet quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000029 platelet count 1388 x 1000 cells/ul 216.06 683.2417 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106005 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. leukocyte quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000027 white blood cell count 9.42 x 1000 cells/ul 2.25 7.1151 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106016 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. leukocyte quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000027 white blood cell count 10.8 x 1000 cells/ul 1.5 4.7434 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106017 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. neutrophil quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000030 blood neutrophil count 1.48 x 1000 cells/ul 0.85 2.6879 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106028 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. neutrophil quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000030 blood neutrophil count 1.89 x 1000 cells/ul 0.62 1.9606 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106029 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. lymphocyte quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000031 blood lymphocyte count 7.36 x 1000 cells/ul 1.77 5.5972 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106040 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. lymphocyte quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000031 blood lymphocyte count 8.25 x 1000 cells/ul 1.31 4.1426 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106041 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. monocyte quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000032 blood monocyte count 0.29 x 1000 cells/ul 0.14 0.4427 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106052 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. monocyte quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000032 blood monocyte count 0.31 x 1000 cells/ul 0.09 0.2846 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106053 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. eosinophil quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000033 blood eosinophil count 0.13 x 1000 cells/ul 0.14 0.4427 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106064 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. eosinophil quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000033 blood eosinophil count 0.18 x 1000 cells/ul 0.18 0.5692 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106065 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. basophil quantity RS:0000698 Hsd:SD female 84 days 10 CMO:0000034 blood basophil count 0.07 x 1000 cells/ul 0.03 0.0949 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106076 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. basophil quantity RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000034 blood basophil count 0.08 x 1000 cells/ul 0.02 0.0632 MMO:0000174 automated hematology analysis vehicle control condition (5 ml/kg) (for 28 days) 106077 vehicle control condition (5 ml/kg) (for 28 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount serum total cholesterol RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000363 serum total cholesterol level 60 mg/dl 2.2136 7.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107892 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount serum alkaline phosphatase RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000577 serum alkaline phosphatase activity level 620 U/l 7.2732 23.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107914 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003517 CD3+ thymocyte count cd3+ thymocyte 1021.26 x10E6/organ 145.57 460.3328 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107715 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003527 CD4+CD8- thymocyte count cd4+cd8- t-cell 239.75 x 10E6/organ 50.38 159.3155 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107718 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003528 CD4+CD8+ thymocyte count cd4+cd8+ t-cell 596.53 x10E6/organ 88.59 280.1462 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107721 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003529 CD4-CD8+ thymocyte count cd4-cd8+ t-cell 74.18 x10E6/organ 11.97 37.8525 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107724 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003530 CD4+CD25+ thymocyte count cd4+cd25+ t-cell 40.63 x10E6/organ 7.77 24.5709 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107727 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003537 CD4+CD25- splenocyte count to total splenocyte count ratio cd4+cd25- spleen 27.9 % 0.69 2.182 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107730 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003539 CD3+ splenocyte count to total splenocyte count ratio cd3- spleen 30.13 % 0.75 2.3717 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107733 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003540 CD11b/c+ splenocyte count to total splenocyte count ratio cd11b/c+ spleen 12.4 % 0.81 2.5614 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107736 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0003534 CD11b/c+ splenocyte count cd11b/c+ spleen 92.63 x10E6/organ 24.28 76.7801 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107739 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003538 CD4+CD25+ splenocyte count to total splenocyte count ratio cd4+cd25+ spleen 1.7 % 0.17 0.5376 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107742 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003541 CD45RA+ splenocyte count to total splenocyte count ratio cd45 RA+ spleen 34.86 % 1.36 4.3007 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107745 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003540 CD11b/c+ splenocyte count to total splenocyte count ratio cd11b/c+ spleen 8.4 % 1.11 3.5101 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107748 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003531 CD4+CD25+ splenocyte count cd4+cd25+ spleen 9.83 x10E6/organ 0.94 2.9725 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107751 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003542 CD4-CD25+ splenocyte count cd4-cd25+ spleen 3.21 x 10E6/organ 0.57 1.8025 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107754 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003533 CD3+ splenocyte count cd3+ spleen 214.09 x10E6/organ 11.49 36.3346 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107757 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. splenocyte morphology trait RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003534 CD11b/c+ splenocyte count cd11b/c+ spleen 50.17 x10E6/organ 10.65 33.6783 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107760 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003517 CD3+ thymocyte count cd3+ thymus 716.82 x10E6/organ 91.79 290.2655 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107763 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003528 CD4+CD8+ thymocyte count cd4+cd8+ t-cell 419 x10E6/organ 50.57 159.9164 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107766 vehicle control condition (2 ml/kg) (for 1 days) 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. urine output RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0001968 timed urine volume to body weight ratio 0.0218736 ul/min/g 0.0024 0.0075 MMO:0000357 urine volume measurement method 0.0 vehicle control condition (for 547.5 days) 107429 vehicle control condition (for 547.5 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount serum triglyceride level RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000360 serum triglyceride level 249 mg/dl 6.957 22.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107899 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003187 retinal uptake index of quinidine quinidine uptake index 212 % 13.0 22.5167 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106114 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003184 retinal uptake index of digoxin digoxin uptake index 24 % 5.8 10.0459 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106117 tritiated digoxin (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003178 retinal uptake index of verapamil verapamil uptake index 336 % 7.0 12.1244 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106120 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003187 retinal uptake index of quinidine quinidine uptake index 227 % 25.0 43.3013 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106123 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003184 retinal uptake index of digoxin digoxin uptake index 88 % 29.7 51.4419 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106126 tritiated digoxin (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. retina blood vessel morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003178 retinal uptake index of verapamil verapamil uptake index 536 % 6.0 10.3923 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106129 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. aqueous humor morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003185 aqueous humor uptake index of quinidine quinidine uptake index 5.95 % 0.38 0.6582 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106132 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. aqueous humor morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 49 days to 35 days 3 CMO:0003182 aqueous humor uptake index of digoxin digoxin uptake index 55.9 % 13.2 22.8631 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106144 tritiated digoxin (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. aqueous humor morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003179 aqueous humor uptake index of verapamil verapamil uptake index 24.8 % 1.4 2.4249 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106147 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003186 brain uptake index of quinidine quinidine uptake index 2.12 % 0.12 0.2078 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106150 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003183 brain uptake index of digoxin digoxin uptake index 0.987 % 0.35 0.6062 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106153 tritiated digoxin (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003177 brain uptake index of verapamil verapamil uptake index 9.07 % 0.89 1.5415 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106156 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003186 brain uptake index of quinidine quinidine uptake index 26.1 % 2.4 4.1569 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition 106159 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. glomerular filtration trait RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0001211 creatinine clearance to body weight ratio 0.38241 ml/min/100g 0.0267 0.0843 MMO:0000306 plasma creatinine analysis 0.0 vehicle control condition (for 547.5 days) 107441 vehicle control condition (for 547.5 days) 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. locomotor behavior trait RS:0003328 SS/NEisSlc not specified 236 days to 63 days 10 CMO:0001037 time to first movement outside a discrete space in an experimental apparatus 235 s 50.0 158.1139 MMO:0000725 passive avoidance test using a two-way shuttle box apparatus 0.0 passive avoidance test using a two-way shuttle box apparatus (MMO:000072) electric foot shock 18 days vehicle control condition (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) 107468 vehicle control condition (for 547.5 days) tactile electric shock exposure (500 mA) (for 0 hours) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount serum bilirubin RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000376 serum total bilirubin level 0.4 mg/dl 0.0316 0.1 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107924 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount serum bilirubin RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000376 serum total bilirubin level 0.35 mg/dl 0.1581 0.5 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107926 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000668 serum lactate dehydrogenase activity level 964 U/l 31.3065 99.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107929 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000668 serum lactate dehydrogenase activity level 2717 U/l 163.1735 516.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107931 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3015 Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015. blood interleukin-4 amount RS:0000681 SD not specified 0 days 4 CMO:0003066 serum interleukin-4 level error not defined 0.14 ug/l 0.005 0.01 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) 105411 vehicle control condition acetic acid (for 0 hours) physical restraint in tube type rodent restrainer (for 2 hours) fasting (for 1 days) 3015 Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015. blood interleukin-9 amount RS:0000681 SD not specified 0 days 4 CMO:0003068 serum interleukin-9 level error not defined 0.1 ug/l 0.005 0.01 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) 105415 vehicle control condition acetic acid (for 0 hours) physical restraint in tube type rodent restrainer (for 2 hours) fasting (for 1 days) 3015 Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015. intestine trypsin amount RS:0000681 SD not specified 0 days 4 CMO:0003072 intestine trypsin level error not defined 0.17 ug/l 0.005 0.01 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) 105419 vehicle control condition acetic acid (for 0 hours) physical restraint in tube type rodent restrainer (for 2 hours) fasting (for 1 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal outer nuclear layer morphology trait RS:0000064 Crl:CD(SD) male 66 days to 59 days 5 CMO:0003086 retinal outer nuclear layer thickness outer nuc layer 41 um 1.118 2.5 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (0 mg/kg) (for 5 days) 105434 vehicle control condition (0 mg/kg) (for 5 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 66 days to 59 days 5 CMO:0003083 retinal outer layer thickness outer retinal layer 142.2 um 2.6833 6.0 MMO:0000696 optical coherence tomography 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 5 days) 105466 vehicle control condition (0 mg/kg) (for 5 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 74 days to 67 days 5 CMO:0003083 retinal outer layer thickness outer retinal layer 138.5 um 3.3988 7.6 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 13 days) 105474 vehicle control condition (0 mg/kg) (for 13 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 87 days to 80 days 10 CMO:0003083 retinal outer layer thickness outer retinal layer 136 um 3.4883 7.8 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 26 days) 105482 vehicle control condition (0 mg/kg) (for 26 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. liver mass RS:0000698 Hsd:SD female 84 days 10 CMO:0000141 liver weight as percentage of body weight 3.647 % 0.199 0.6293 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (5 ml/kg) (for 28 days) 105720 vehicle control condition (5 ml/kg) (for 28 days) 3021 Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17. liver mass RS:0004674 SD-Ahrem2Sage female 84 days 10 CMO:0000141 liver weight as percentage of body weight 3.428 % 0.3 0.9487 MMO:0000005 post excision weight measurement 0.0 vehicle control condition (5 ml/kg) (for 28 days) 105726 vehicle control condition (5 ml/kg) (for 28 days) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003183 brain uptake index of digoxin digoxin uptake index 14 % 7.3 12.644 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition 106162 tritiated digoxin (10 uCi) (for 0 hours) vehicle control condition 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. blood-brain barrier morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003177 brain uptake index of verapamil verapamil uptake index 75 % 5.8 10.0459 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition 106165 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood enzyme amount RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0003487 serum NAG activity level serum NAG activity level (CMO:0003487) 20.1 uU/ml 1.9 6.0083 MMO:0000723 blood NAG activity assay 0.0 blood NAG activity assay (MMO:0000723) vehicle control condition (for 547.5 days) 107425 vehicle control condition (for 547.5 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003529 CD4-CD8+ thymocyte count cd4-cd8+ t-cell 63.99 x10E6/organ 6.25 19.7642 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107769 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. thymocyte quantity RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0003530 CD4+CD25+ thymocyte count cd4+cd25+ t-cell 32.19 x10E6/organ 7.15 22.6103 MMO:0000617 flow cytometry method 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107772 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood triglyceride amount RS:0003766 WAG/Nov male 180 days to 150 days 10 CMO:0000548 plasma triglyceride level 1.1865 mmol/l 0.0915 0.2894 MMO:0000234 plasma triglyceride analysis 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107775 vehicle control condition (2 ml/kg) (for 1 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. blood triglyceride amount RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0000548 plasma triglyceride level 1.2995 mmol/l 0.1153 0.3645 MMO:0000234 plasma triglyceride analysis 0.0 saline IP injeciton 1 days vehicle control condition (2 ml/kg) (for 1 days) 107778 vehicle control condition (2 ml/kg) (for 1 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal outer nuclear layer morphology trait RS:0000064 Crl:CD(SD) male 88 days to 81 days 5 CMO:0003086 retinal outer nuclear layer thickness outer nuc layer 53.4 um 2.3255 5.2 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (0 mg/kg) (for 25 days) 105442 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal outer nuclear layer morphology trait RS:0000064 Crl:CD(SD) male 144 days to 137 days 5 CMO:0003085 retinal outer nuclear layer photoreceptor nucleus count nuclei per cell 10.5 0.4025 0.9 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 vehicle control condition (for 25 days) 105462 vehicle control condition (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 87 days to 80 days 10 CMO:0003084 retinal inner layer thickness inner retinal layer 126 um 4.0249 9.0 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 26 days) 105486 vehicle control condition (0 mg/kg) (for 26 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 118 days to 111 days 5 CMO:0003083 retinal outer layer thickness outer retinal layer 132.2 um 3.7119 8.3 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 25 days) 105490 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 143 days to 136 days 5 CMO:0003083 retinal outer layer thickness outer retinal layer 129.8 um 4.0249 9.0 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 25 days) 105498 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 143 days to 136 days 5 CMO:0003084 retinal inner layer thickness inner retinal layer 123.8 um 4.8299 10.8 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 25 days) 105502 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 66 days to 59 days 5 CMO:0003082 full retina thickness full retina layer 129.7 um 3.7119 8.3 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (0 mg/kg) (for 5 days) 105438 vehicle control condition (0 mg/kg) (for 5 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal outer nuclear layer morphology trait RS:0000064 Crl:CD(SD) male 88 days to 81 days 5 CMO:0003085 retinal outer nuclear layer photoreceptor nucleus count nuclei per cell 11.3 0.3712 0.83 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 vehicle control condition (0 mg/kg) (for 25 days) 105450 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal outer nuclear layer morphology trait RS:0000064 Crl:CD(SD) male 144 days to 137 days 5 CMO:0003086 retinal outer nuclear layer thickness outer nuc layer 50.6 um 1.61 3.6 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (for 25 days) 105454 vehicle control condition (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 144 days to 137 days 5 CMO:0003082 full retina thickness full retina layer 191.6 um 7.5579 16.9 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (0 mg/kg) (for 25 days) 105458 vehicle control condition (0 mg/kg) (for 25 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 66 days to 59 days 5 CMO:0003084 retinal inner layer thickness inner retinal layer 131.6 um 4.8746 10.9 MMO:0000696 optical coherence tomography 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 5 days) 105470 vehicle control condition (0 mg/kg) (for 5 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 74 days to 67 days 5 CMO:0003084 retinal inner layer thickness inner retinal layer 128.7 um 4.9193 11.0 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 13 days) 105478 vehicle control condition (0 mg/kg) (for 13 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 118 days to 111 days 5 CMO:0003084 retinal inner layer thickness inner retinal layer 121.9 um 4.3827 9.8 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 optical coherence tomography vehicle control condition (0 mg/kg) (for 25 days) 105494 vehicle control condition (0 mg/kg) (for 25 days) 3029 Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70. cerebrum integrity trait RS:0001696 F344-Pde4dTn(sb-T2/Bart3)2.285Mcwi male 0 days 6 CMO:0003169 cerebrum infarct volume to total cerebrum volume ratio 20 % 9.0 22.0454 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 cerebral ischemia 1 days isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) 106360 isoflurane (1.5 %) (for 4 hours) vehicle control condition middle cerebral artery occlusion (for 1 hours) 3015 Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015. blood immunoglobulin E amount RS:0000681 SD not specified 0 days 4 CMO:0001542 serum total immunoglobulin E level error not defined 0.2 ug/l 0.0 0.0 MMO:0000075 enzyme linked immunosorbent assay 0.0 vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) 105407 vehicle control condition acetic acid (for 0 hours) physical restraint in tube type rodent restrainer (for 2 hours) fasting (for 1 days) 3016 Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31. retinal layer morphology trait RS:0000064 Crl:CD(SD) male 88 days to 81 days 5 CMO:0003082 full retina thickness full retina layer 177.2 um 6.2163 13.9 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 vehicle control condition (0 mg/kg) (for 25 days) 105446 vehicle control condition (0 mg/kg) (for 25 days) 3018 Westlund KN, et al., Neuroscience. 2014 Mar 14;262:165-75. doi: 10.1016/j.neuroscience.2013.12.043. Epub 2014 Jan 3. voluntary movement trait RS:0000215 F344 male 0 days 4 CMO:0003680 measurement of the 50% threshold of mechanical stimulus needed to elicit evasive reaction both paws 2.88 g 0.44 0.88 MMO:0000752 von Frey assay 1500.0 von Frey assay (MMO:0000752) vehicle control condition 105566 vehicle control condition 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. life span trait RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 12 CMO:0003630 ratio of survivors of severe albuminuria to total study population during a period of time ratio of survivors of severe albuminuria to total study population during a period of time (CMO:0003630) 50 % MMO:0000160 unspecified method 0.0 controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 109030 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. aqueous humor morphology trait RS:0000681 SD male 49 days to 35 days 3 CMO:0003179 aqueous humor uptake index of verapamil verapamil uptake index 8.46 % 0.61 1.0566 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106138 tritiated verapamil (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3028 Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819. aqueous humor morphology trait RS:0004432 SD-Abcb1aem1Sage-/- male 56 days to 42 days 3 CMO:0003185 aqueous humor uptake index of quinidine quinidine uptake index 12 % 0.6 1.0392 MMO:0000238 liquid scintillation counting 0.0 sec post excision carotid injection 15 tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) 106141 tritiated quinidine (10 uCi) (for 0 hours) vehicle control condition (for 0 hours) 3029 Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70. cerebrum integrity trait RS:0001013 WI male 0 days 16 CMO:0003169 cerebrum infarct volume to total cerebrum volume ratio 23 % 3.0 12.0 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 cerebral ischemia 1 days isoflurane (1.5 %) (for 4 hours) then vehicle control condition then Embolism injection at middle cerebral artery (for 1 days) 106358 isoflurane (1.5 %) (for 4 hours) vehicle control condition Embolism injection at middle cerebral artery (for 1 days) 3029 Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70. cerebrum integrity trait RS:0000215 F344 male 0 days 18 CMO:0003169 cerebrum infarct volume to total cerebrum volume ratio 11 % 2.0 8.4853 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 cerebral ischemia 1 days isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) 106172 isoflurane (1.5 %) (for 4 hours) vehicle control condition middle cerebral artery occlusion (for 1 hours) 3029 Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70. cerebrum integrity trait RS:0000215 F344 male 0 days 6 CMO:0003169 cerebrum infarct volume to total cerebrum volume ratio 18 % 6.0 14.6969 MMO:0000560 ex vivo light microscopy with histochemistry and digital image analysis 0.0 cerebral ischemia 1 days isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) 106361 isoflurane (1.5 %) (for 4 hours) vehicle control condition middle cerebral artery occlusion (for 1 hours) 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003280 heart right ventricle weight to left ventricle plus septum weight ratio heart right ventricle weight to left ventricle plus septum weight ratio 0.25 g/g 0.02 0.0529 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106536 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003280 heart right ventricle weight to left ventricle plus septum weight ratio heart right ventricle weight to left ventricle plus septum weight ratio 0.25 g/g 0.01 0.0316 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106537 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000776 heart left ventricle weight 0.641 g 0.0193 0.0511 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106538 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000776 heart left ventricle weight 0.64 g 0.0094 0.0297 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106539 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000777 heart right ventricle weight 0.162 g 0.0067 0.0177 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106540 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000777 heart right ventricle weight 0.157 g 0.0028 0.0089 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106541 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. body mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000012 body weight 261 g 6.0 15.8745 MMO:0000016 body weighing method 0.0 vehicle control condition 106550 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. body mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000012 body weight 259 g 2.8 8.8544 MMO:0000016 body weighing method 0.0 vehicle control condition 106551 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. tibia length RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000450 tibia length 3.64 cm 0.06 0.1587 MMO:0000276 post excision length measurement 0.0 vehicle control condition 106554 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. tibia length RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000450 tibia length 3.64 cm 0.03 0.0949 MMO:0000276 post excision length measurement 0.0 vehicle control condition 106555 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000096 lung weight 1.23 g 0.05 0.1323 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106558 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000096 lung weight 1.2 g 0.01 0.0316 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106559 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000336 right atrium weight 0.0161 g 0.0012 0.0032 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106562 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000336 right atrium weight 0.0149 g 0.0011 0.0036 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106563 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000335 left atrium weight 0.0148 g 7.0E-4 0.0019 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106566 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000335 left atrium weight 0.0164 g 0.0011 0.0035 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106567 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003191 heart right atrium weight to left atrium weight ratio 1.09 0.09 0.2381 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106570 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003191 heart right atrium weight to left atrium weight ratio 0.94 0.09 0.2846 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106571 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000092 liver weight 10.6 g 0.42 1.1112 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106574 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000092 liver weight 10.6 g 0.22 0.6957 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106575 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000081 kidney weight 2.13 g 0.05 0.1323 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106578 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000081 kidney weight 2.03 g 0.03 0.0949 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106579 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000914 heart right ventricle weight to body weight ratio 0.62 mg/g 0.03 0.0794 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106582 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000914 heart right ventricle weight to body weight ratio 0.61 mg/g 0.01 0.0316 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106583 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000530 heart left ventricle weight to body weight ratio 2.43 mg/g 0.05 0.1323 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106586 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000530 heart left ventricle weight to body weight ratio 2.49 mg/g 0.03 0.0949 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106587 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000156 lung weight to body weight ratio 0.403 % 0.076 0.2011 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106590 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000156 lung weight to body weight ratio 0.465 % 0.007 0.0221 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106591 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0002952 heart right atrium weight to body weight ratio 0.06 mg/g 0.01 0.0265 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106594 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0002952 heart right atrium weight to body weight ratio 0.06 mg/g 0.01 0.0316 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106595 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0002950 heart left atrium weight to body weight ratio 0.06 mg/g 0.01 0.0265 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106598 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0002950 heart left atrium weight to body weight ratio 0.06 mg/g 0.01 0.0316 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106599 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000633 liver weight to body weight ratio 40.5 g/kg 1.02 2.6987 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106602 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000633 liver weight to body weight ratio 40.9 g/kg 0.77 2.435 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106603 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0000622 single kidney wet weight to body weight ratio 8.14 g/kg 0.11 0.291 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106606 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0000622 single kidney wet weight to body weight ratio 7.83 g/kg 0.15 0.4743 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106607 vehicle control condition 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. arterial blood pressure trait RS:0000775 SHRSP/A3N male 189 days to 168 days 6 CMO:0000004 systolic blood pressure serial mean 284 mmHg 8.0 19.5959 MMO:0000031 tail cuff plethysmography tail 0.0 average 3 week intervals for 12 weeks controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and vehicle control condition (for 84 days) 107499 controlled sodium chloride content drinking water (1 %) (for 84 days) controlled fat content diet (24.5 %) (for 84 days) vehicle control condition (for 84 days) 3096 Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4. leukocyte quantity RS:0001334 ISIAH male 180 days to 150 days 10 CMO:0002340 blood non-specified leukocyte count 2.96 10E3/ul 0.99 3.1307 MMO:0000533 white blood cell counting method 0.0 saline IP injection 1 days vehicle control condition (2 ml/kg) (for 1 days) 107696 vehicle control condition (2 ml/kg) (for 1 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0000340 both kidneys wet weight to body weight ratio 13 g/kg 0.7 MMO:0000005 post excision weight measurement kidney 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107535 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3090 Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney glomerulus integrity trait RS:0000775 SHRSP/A3N male 182 days to 126 days N/A CMO:0003447 kidney glomerular lesion count 76.5 /section 7.0 MMO:0000561 ex vivo light microscopy with histochemistry renal glomerulus 0.0 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) 107539 controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) controlled fat content diet (24.5 %) (between 42 and 77 days) vehicle control condition (between 42 and 77 days) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000290 mean corpuscular hemoglobin 18 pg 0.0632 0.2 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107836 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000290 mean corpuscular hemoglobin 17.5 pg 0.0316 0.1 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107838 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000291 mean corpuscular hemoglobin concentration 38 g/dl 0.1265 0.4 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107841 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount hemoglobin, MCH, MCHC RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000291 mean corpuscular hemoglobin concentration 37 g/dl 0.1897 0.6 MMO:0000295 blood hemoglobin analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107843 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait MCV, RDW% RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000041 red blood cell distribution width-coefficient of variation 16.9 % 0.2214 0.7 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107846 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait MCV, RDW% RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000041 red blood cell distribution width-coefficient of variation 17.7 % 0.1265 0.4 MMO:0000174 automated hematology analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107848 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity LYM RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000371 blood lymphocyte count to total leukocyte count ratio 8.1 % 0.253 0.8 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107851 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity LYM RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000371 blood lymphocyte count to total leukocyte count ratio 8 % 0.0949 0.3 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107853 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount serum triglyceride level RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000360 serum triglyceride level 265 mg/dl 8.2219 26.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107897 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount serum aspartate aminotransferase RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000581 serum aspartate aminotransferase activity level 139 U/l 2.5931 8.2 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107902 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount serum aspartate aminotransferase RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000581 serum aspartate aminotransferase activity level 193 U/l 8.2219 26.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107904 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount serum amylase RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0003519 serum amylase activity level 3190 U/l 77.1596 244.0 MMO:0000554 automated serum analysis 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107946 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003188 heart right ventricle weight to tibia length ratio 4.51 mg/mm 0.22 0.5821 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106610 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003188 heart right ventricle weight to tibia length ratio 4.33 mg/mm 0.97 3.0674 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106611 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0002787 heart left ventricle weight to tibia length ratio 0.178 g/cm 0.0069 0.0183 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106614 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left ventricle mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0002787 heart left ventricle weight to tibia length ratio 0.177 g/cm 0.0027 0.0085 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106615 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003144 lung weight to tibia length ratio 0.291 g/cm 0.0455 0.1204 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106618 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. lung mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003144 lung weight to tibia length ratio 0.33 g/cm 0.004 0.0126 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106619 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003192 heart right atrium weight to tibia length ratio 0.44 mg/mm 0.036 0.0952 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106622 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart right atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003192 heart right atrium weight to tibia length ratio 0.41 mg/mm 0.03 0.0949 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106623 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003193 heart left atrium weight to tibia length ratio 0.41 mg/mm 0.02 0.0529 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106626 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. heart left atrium mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003193 heart left atrium weight to tibia length ratio 0.45 mg/mm 0.03 0.0949 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106627 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0002995 liver weight to tibia length ratio 29.2 mg/mm 1.28 3.3866 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106630 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. liver mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0002995 liver weight to tibia length ratio 29.1 mg/mm 0.66 2.0871 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106631 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0000811 SS/JrHsdMcwi male 56 days 7 CMO:0003145 single kidney weight to tibia length ratio 0.0586 g/cm 0.0018 0.0048 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106634 vehicle control condition 3032 Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. kidney mass RS:0001480 SS-Sod3m1Mcwi male 56 days 10 CMO:0003145 single kidney weight to tibia length ratio 0.0556 g/cm 0.0011 0.0035 MMO:0000005 post excision weight measurement 0.0 vehicle control condition 106635 vehicle control condition 2339 Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. hippocampus neuron quantity RS:0003328 SS/NEisSlc not specified 547 days 10 CMO:0000328 neuron count 1258 cells/mm2 32.0 101.1929 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 vehicle control condition (for 547.5 days) 107465 vehicle control condition (for 547.5 days) 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass RS:0000742 WKY male 0 days 11 CMO:0001954 left kidney wet weight to body weight ratio 3.9 mg/g 0.1 0.3317 MMO:0000005 post excision weight measurement 0.0 unx 150 days unilateral nephrectomy (for 150 days) then vehicle control condition 107455 unilateral nephrectomy (for 150 days) vehicle control condition 2378 Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait RS:0000742 WKY male 0 days 11 CMO:0003488 kidney glomerular surface area kidney glomerulus surface area (CMO:0003488) 12.6 x 10E3 um2 3.8 12.6032 MMO:0000561 ex vivo light microscopy with histochemistry 0.0 unx 150 days unilateral nephrectomy (for 150 days) then vehicle control condition 107460 unilateral nephrectomy (for 150 days) vehicle control condition 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000367 blood granulocyte count to total leukocyte count ratio 1.2 % 0.0 0.0 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107856 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000367 blood granulocyte count to total leukocyte count ratio 0.8 % 0.0 0.0 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107858 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity LYM RS:0001789 BDIX/CrCrl male 71 days 10 CMO:0000031 blood lymphocyte count 62.8 x 1000 cells/ul 0.3162 1.0 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107861 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3097 Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity LYM RS:0001789 BDIX/CrCrl male 92 days 10 CMO:0000031 blood lymphocyte count 77.7 x 1000 cells/ul 0.6325 2.0 MMO:0000145 automated differential white blood cell count test 0.0 DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107863 DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. xenobiotic metabolism trait RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0003440 time to peak measurement of Gd-DTPA uptake by kidney cortex 5 seconds x 10 measurements averaged x 8 regions 14.3 s 1.2 17.98 MMO:0000718 Dynamic Contrast-Enhanced Magnetic Resonance Imaging cortex of kidney 400.0 5 seconds x 10 measurements averaged x 8 regions controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 107374 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. glomerular filtration trait RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0003631 multiregional glomerular filtration rate index dCm/dt = KclCc(t) glomerular filtration rate index 2.25 mmol/min 0.14 0.3429 MMO:0000718 Dynamic Contrast-Enhanced Magnetic Resonance Imaging 400.0 5 sec x 10 measurements x 8 regions controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (between 35 and 63 days) 107379 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (between 35 and 63 days) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. body mass RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0000012 body weight 307 g 8.0 19.5959 MMO:0000016 body weighing method 0.0 controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 107382 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. arterial blood pressure trait RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0000004 systolic blood pressure 162 mmHg 4.0 9.798 MMO:0000031 tail cuff plethysmography 0.0 controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 107385 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. glomerular filtration trait RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0000765 creatinine clearance 2 ml/min 0.2 0.4899 MMO:0000275 urine creatinine analysis 0.0 controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 107388 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3083 Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. blood urea nitrogen amount RS:0002538 SHRSP/A3NCrl male 175 days to 161 days 6 CMO:0000049 blood urea nitrogen level 20.5 mg/dl 5.8 14.207 MMO:0000253 blood urea nitrogen analysis 0.0 controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) 107391 controlled sodium chloride content drinking water (1 %) (for 91 days) controlled fat content diet (24.5 %) (for 91 days) vehicle control condition (for 35 days) 3154 Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. cone electrophysiology trait RS:0000655 RCS-p+/LavRrrc not specified 119 days 7 CMO:0003702 photopic B wave amplitude of ERG waveform 23.1 uV 1.0 2.6458 MMO:0000616 electroretinography cornea 0.0 intravitrial injection 98 days vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) 109739 vehicle control condition (2 ul) visible light stimulus (25 cd x s/m2) 3154 Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. eye physiology trait RS:0000655 RCS-p+/LavRrrc not specified 119 days 7 CMO:0003729 optokinetic reflex 6 s 0.27 0.7144 MMO:0000754 optokinetic reflex test method 60.0 intravitrial injection 98 days vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) 109741 vehicle control condition (2 ul) visible light stimulus (25 cd x s/m2) 3157 Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait RS:0000660 RCS/LavRrrc not specified 35 days 4 CMO:0003705 scotopic B wave amplitude of ERG waveform 95.22 uV 16.19 32.38 MMO:0000616 electroretinography retina 0.0 pbs vehicle injection 14 days vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus 109856 vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours) visible light stimulus 3157 Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait RS:0000660 RCS/LavRrrc not specified 77 days 4 CMO:0003705 scotopic B wave amplitude of ERG waveform 13.01 uV 1.845 3.69 MMO:0000616 electroretinography retina 0.0 pbs vehicle injection 56 days vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus 109862 vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours) visible light stimulus 3157 Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait RS:0000660 RCS/LavRrrc not specified 49 days 4 CMO:0003705 scotopic B wave amplitude of ERG waveform 29.44 uV 7.435 14.87 MMO:0000616 electroretinography retina 0.0 pbs vehicle injection 28 days vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus 109859 vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours) visible light stimulus 3155 van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50. hypodermis integrity trait RS:0004900 LOU/MWsl male 130 days 8 CMO:0003700 subcutaneous tumor diameter measurement 37.2 mm 1.1314 3.2 MMO:0000159 in vivo caliper method hindlimb 0.0 mean of 3 measurements 28 days rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 28 days) 109745 rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) vehicle control condition (1 ml/kg) (for 28 days) 3155 van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50. blood albumin amount RS:0004900 LOU/MWsl male 109 days 5 CMO:0000550 serum albumin level 219 g/dl 13.8636 31.0 MMO:0000100 gel electrophoresis 0.0 rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 7 days) 109761 rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) vehicle control condition (1 ml/kg) (for 7 days)